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ABSTRACT 
FUNCTIONAL ANALYSIS OF N-ACETYL TRANSFERASE (NAT1 *148 AND 
NAT1*10) IN COMPLETE NATb AND NATa mRNA 
Lori Millner 
August 8, 2011 
N-acetyltransferase 1 (NAT1) is a phase II metabolic enzyme responsible for the 
biotransformation of aromatic and heterocyclic amine carcinogens such as 4-
aminobiphenyl (ASP). NAT1 catalyzes N-acetylation of arylamines as well as the 0-
acetylation of N-hydroxylated arylamines. O-acetylation leads to the formation of 
electrophilic intermediates that result in DNA adducts and mutations. NAT1 is 
transcribed from a major promoter, NATb, and an alternative promoter, NATa, resulting 
in mRNAs with distinct 5'-untranslated regions (UTR). NATa mRNA is expressed 
primarily in the kidney, liver, trachea and lung while NATb mRNA has been detected in 
all tissues studied. To determine if differences in 5'-UTR have functional effect upon 
NAT1 activity and DNA adducts or mutations following exposure to ASP, pcDNA5/FRT 
plasmid constructs were prepared for transfection of full length human mRNAs including 
the 5'-UTR derived from NATa or NATb, the open reading frame, and 888 nucleotides of 
the 3'-UTR. Following stable transfection of NATb/NAT1*4 or NATa/NAT1*4 into 
nucleotide excision repair (NER) deficient Chinese hamster ovary cells, N- and 0-
acetyltransferase activity (in vitro and in situ), mRNA, and protein expression were 
higher in NATb/NAT1*4 than NATa/NAT1*4 transfected cells (p<O.05). Consistent with 
NAT1 expression and activity, ASP-induced DNA adducts and hypoxanthine 
phosphoribosy/ transferase mutants were higher (p<O.05) in NATb/NA T1 *4 than in 
v 
NAT alNA T1 *4 transfected cells following exposure to ABP. These NATa and NA Tb 
mRNA constructs have also been used to study variant NAT1 alleles, including 
NA T1 *14B and NA T1 *10. NA T1 *14B is the most common allele associated with 
reduced N-acetylation activity and has been associated with increased risk for smoking 
induced lung cancer. NA Tbl NA T1 *14B transfected cells resulted in lower V max for PABA, 
ABP, and N-OH-ABP compared to cells transfected with NATb/NAT1*4. However, cells 
transfected with NATblNA T1*14B resulted in increased VmaxfKm for ABP and N-OH-ABP. 
Cells transfected with NATblNA T1 *14B also resulted in increased ABP-induced DNA-
adducts compared to cells transfected with NATblNA T1 *4 transfected cell. This 
indicates that NAT1 14B has lowered capacity for N- and 0- ABP acetylation at high 
substrate concentrations but higher capacity at low substrate concentration when 
compared to NAT1 4. NAT1 14B VmaxfKm compared to NAT1 4 was lower for PABA but 
higher for ABP and N-OH-ABP. This indicates that NAT1 14B is not simply associated 
with lowered acetylation, but is substrate dependent. Another variant allele, NA T1 *10 is 
the most common variant allele in many populations and has been characterized by 
increased acetylation activity in colon and bladder. NA T1 *10 has been associated with 
increased cancer risk for prostate, breast, urinary bladder cancer, gastric 
adenocarcinoma, colon cancers and non-Hodgkin's lymphoma. Following sequencing of 
NAT1*10 genomic sources, additional polymorphisms (A1642C, f1CT1647, C1716T, and 
A 1735T) were observed in one source. This allele is referred to as NA T1 *1 OB in this 
dissertation. Cells transfected with NA Tbl NA T1 *10 and NA Tbl NA T1 *1 OB resulted in 
higher NAT1 activity, protein, mRNA, ABP-induced mutants and DNA adducts than cells 
transfected with NATblNA T1 *4. Differences between NAT1 4, NAT1 10, and NAT1 10B 
were also observed in NATa constructs. These studies illustrate the importance of 
determining NAT1 phenotypes and cancer risk based on mRNA type, substrate type and 
concentration. 
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CHAPTER 1 
ARYLAMINE N-ACETYL TRANSFERASE: AN INTRODUCTION 
Arylamine N-acetyltransferases (NAT1 and NAT2) are an important family of 
cytosolic, phase II xenobiotic metabolizing enzymes. They are found in most species 
from prokaryotes to eukaryotes (Boukouvala and Fakis, 2005). The N-acetyltransferase 
(NAT) genes were among the first polymorphic genes to be identified, over 40 years 
ago. The discovery occurred in the 1950s when a new drug, isoniazid, was introduced 
to treat tuberculosis. Isoniazid was largely successful in treating tuberculosis, however a 
small percentage of patients experienced severe side effects including peripheral 
neuropathy and liver toxicity during treatment (Biehl and Sklavem, 1953). Following 
publication of biomodal distribution histograms measuring the amount of unchanged 
isoniazid in urine, it was determined that two groups of acetylators (rapid and slow) 
existed (Evans et aI., 1960). It was also determined that the patients with the highest 
plasma isoniazid levels were generally slow acetylators (Evans et aI., 1960) and that 
slow acetylators were most likely to develop side effects (Clark, 1985). It was later 
discovered that NAT2 was responsible for the metabolism of not only isoniazid, but also 
other hydrazine drugs including the monoamine oxidase inhibitor, phenelzine, and the 
anti-hypertensive drug, hydralazine (Weber and Hein, 1985). NAT is also responsible for 
the detoxification of many arylamine drugs such as antibacterial sulfonamides the 
antiarrhythmic drug procainamide, the antibiotic dapsone, and the aromatase inhibitor 













Figure 1-1: Drugs metabolized by NAT2 
Drugs metabolized by NAT2 include the antitubercular drug isoniazid, the anti-
hypertensive drug hydralazine, the monoamine oxidase inhibitor phenelzine, the 
aromatase inhibitor aminoglutethimide, the antibiotic dapsone, the antiarrhythmic 
drug procainamide, and the antibacterial drug sulfamethazine. 
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In addition to drug metabolism, NAT1 and NAT2 are responsible for the 
metabolism of many arylamine carcinogens. Common environmental arylamine 
carcinogens metabolized by NAT include aromatic amines such as 4-aminobiphenyl 
(ASP) and 2-aminofluorene (AF) that are components of cigarette smoke and 
contaminants in many products including hair and textile dyes. Heterocyclic amines 
include 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3-
methylimidazo[4,5-f]quinoline (10), and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline 
(Mel Ox) which are found in meats cooked at high temperatures (Refer to Figure1-2). 
Heterocyclic amines form when amino acids come into contact with creatine at high 
temperatures (Keating and Sogen, 2004; Schut and Snyderwine, 1999). 
PhlP 10 
< > < >-N~ 
ABP 
Figure 1-2: Common environmental arylamine carcinogens metabolized by NAT. 
These include 4-aminobiphenyl (ASP), 2-aminofluorene (AF), 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3-methylimidazo[4,5-f]quinoline (10), 2-
amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIOx). 
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Role of human N-acetyltransferases in Carcinogen Metabolism 
Carcinogens may react directly with important biological components such as 
DNA, protein, or lipids, but many carcinogens only exert an effect when metabolically 
activated by phase I or phase II enzymes. Aromatic amines such as ASP contain 
exocyclic amines and may be directly N-acetylated by NAT. NATs catalyze N-acetylation 
(Figure 1-3) by transferring an acetyl group from acetyl-CoA to the exocyclic nitrogen of 
an aromatic or heterocyclic amine. These compounds can then be excreted from the 
body. Arylamine carcinogens are primarily activated in the body by a two step process. 
The first step is N-hydroxylation carried out by the phase I metabolic enzymes, 
cytochrome p450s (Schut and Snyderwine, 1999). These N-hydroxy metabolites can be 
activated further by phase II enzymes such as NAT, sulfotransferases, or tRNA 
synthetases. NAT is an extremely important phase II enzyme. It was found to have the 
highest activity in mammary tissue when compared to the other most common phase II 
enzymes (Ghoshal et aI., 1995). NAT1 and NAT2 further activate N-hydroxy metabolites 
via O-acetylation to form nitreum ions. These acetoxy metabolites quickly form highly 
electrophilic intermediates that react with DNA to form bulky adducts. If these lesions are 
not repaired, mutagenesis and carcinogenesis may result (Schut and Snyderwine, 
1999). The interaction between environmental carcinogen exposure and genes coding 







Figure 1-3: Possible Metabolic Pathways for 4-aminobiphenyl (ABP) 
If the amine group is first N-acetylated creating N-acetyl-ASP, the compound can then 
be excreted. However, If ASP is first hydroxylated by cytochrome p450, creating N-
hydroxy-ASP, NAT can further activate the compound by O-acetylation creating N-
acetoxy-ASP. N-acetoxy-ASP is an extremely unstable compound which spontaneously 
breaks down to form acetic acid and a highly electrophilic arylnitrenium ion that binds 
covalently with nucleophilic moieties such as protein or DNA to form adducts. 
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In addition to activation of environmental carcinogens, NAT1 may serve in a 
more profound role affecting tumor development and progression. NAT1 overexpression 
has been implicated in enhanced density dependent cell growth and resistance to 
chemotherapy. In a recent study conducted in the colon adenocarcinoma cell line HT-
29, a marked change in cell morphology, an increase in cell-cell contact growth inhibition 
and a loss of cell viability at confluence was observed when NAT1 was knocked down 
(Tiang et aI., 2011). Additionally, knock-down of NAT1 resulted in up-regulation of E-
cadherin in both HT-29 cells and in the prostate cancer cell line 22Rv1 (Tiang et aI., 
2011). The overexpression of NAT1 in a normal human mammary luminal epithelial cell 
line (HB4a) allowed those cells to continue proliferation far beyond the density of normal 
HB4a cells (Adam et aI., 2003). The overexpressing HB4a cells also showed resistance 
to etoposide compared to normal HB4a cells, but it is unknown how NAT1 affects 
etoposide resistance (Adam et aI., 2003). It has recently been demonstrated that 
cisplatin interacts with and inhibits NAT1 with the highest second-order rate constant 
among cisplatin targets (Ragunathan et aI., 2008). Therefore, NAT1 up-regulation may 
affect chemotherapeutic tumor sensitivity. Additionally, NAT1 has been identified as one 
of the top three most overexpressed genes in estrogen receptor positive breast tumor 
tissues (Wakefield et aI., 2008). Because NAT1 expression may have far reaching 
effects on tumor growth, progression and chemotherapeutic sensitivity, it is important to 
understand regulation of NA T1 expression. 
NA T1 Gene and Regulation 
The human genome encodes two isoforms of N-acetyltransferase, NAT1 and 
NAT2 located on the short arm of chromosome 8 (Matas et al. 1997). Both are encoded 
by a single intronless coding exon containing an open reading frame (ORF) of 870 base 
pairs. The NAT1 and NAT2 ORFs have 87% nucleotide sequence identity (Sim et aI., 
6 
2000). Although NAT1 and NAT2 enzymes are similar in sequence, they possess 
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Figure 1-4: NAT1 gene structure and common transcripts 
The NAT1 promoters (NATa and NATb) produce several mRNA variants with different 
combinations of 5'-UTR exons. All splice variants identified to date contain both exons 8 
and 9. The NATa promoter drives transcription of Type 1 transcripts, whereas NATb 
drives transcription of Type II transcripts. Modified from Butcher et aL, 2005. 
The NA T1 gene is approximately 53 kb in length and contains at least nine exons 
(Husain et aL, 2004). Many NAT1 transcripts have been identified containing different 
combinations of the 5' UTR exons originating from two separate promoters (Husain et 
aL, 2004; Butcher et aL, 2005). Differences in translational efficiencies exist between 
transcripts originating at each promoter, but the biological importance of this remains 
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unclear (Butcher et aL, 2005). Six different mRNAs have been identified to begin at the 
first promoter, NATa (also known as P3), which is located 50.1 kb upstream of the NAT1 
ORF (Barker et aL, 2006). Five different mRNAs have been identified which begin at the 
second promoter, NA Tb (also known at P 1), located just upstream of exon 4 (11.8 kb of 
the NAT1 ORF) (Butcher et aL, 2005; Husain et aL, 2004) (Figure 1-4). 
The NATb promoter has been mapped to a 213 bp region upstream of exon 4 in 
MCF-7 cells or a 257 bp region in HT-29 cells (Butcher et aL, 2005; Husain et aL, 2007). 
Alignment with promoter sequences of NATs derived from other species revealed a 
conserved 16 bp palindrome and a functional Sp1 element (Husain et aL, 2007). The 
NATb promoter lacks a TATA-box and is therefore likely a TATA-Iess Inr type promoter 
(Smale,1997). Less is known about the alternative, NATa promoter. The NATa 
promoter region has been mapped to a 435 bp region upstream of exon 1 (Barker et aL, 
2006). The relative strength of the NATa promoter was low compared to the NATb 
promoter and pGL3-control (containing the strong SV40 promoter) in HepG2 cells 
(Barker et aL, 2006; Husain et aL, 2004). However, the relative contribution of transcripts 
derived from the NATa promoter is not known. Transcripts derived from the NATb 
promoter have been found in all tissues studied but transcripts derived from the NATa 
promoter have been found in liver, kidney, lung, and trachea (Barker et aL, 2006; Husain 
et aL, 2004). It is possible that NATa transcripts are expressed in a wider range of 
tissues, but only when the cell is under specific environmental stress or in a disease 
state. For example, expression of NATa transcripts has recently been reported in 
several ER-positive breast cancer cell lines where NA T1 overexpression is observed 
(Wakefield et aL, 2008). 
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NA T1 Population Frequencies 
NA T1*4 is present at high frequencies in most populations. The highest NA T1 *4 
allelic frequencies have been reported in the American, French, Canadian, Lebanese, 
Chinese and German populations (Table 1-1). NAT1*4 is not the most frequent allele in 
the South African population, where NAT1*10 has the highest allelic frequency. In the 
Lebanese population, allelic frequency for NAT1*14B is 23.8%, while in most other 
populations the allelic frequency is less than 5% (Table 1). Although the NAT1 allele 
population frequencies included here are not exhaustive, they represent populations 
found on four different continents. 
Table 1-1: NAT1 allelic frequencies in selected populations 
USA South 
(Iowa) France Canada Germany Lebanon China Africa 
Allele (Blacks) 
NATl*4 74.2 74.7 70.3 72.4 56 49.6 48.5 
NATl *10 17.4 17.8 25 20.4 10.7 40 50.5 
NATl *148 2 3.7 2.6 0.6 23.8 ND ND 
(NAT1 allele frequencies from Cascorbi et aI., 2001; Dhaini and Levy et aI., 2001; Lo-
Guidice et aI., 2000; Loktionov et aI., 2002; Vaziri et aI., 2001; Zhangwei et aI., 2006; 
Zheng et aI., 1999). 
NAT1*14B 
NA T1 *14B is the most common NAT1 allele associated with reduced acetylation 
activity. NAT1*14B is characterized by a SNP found in the ORF (560G>A) which causes 
an amino acid substitution (R 187Q). Evidence suggests that NA T1 148 is a slow 
acetylator due to the R187Q substitution which causes decreased or no acetylation 
activity in NAT1 148 (Grant et aI., 1997; Hughes et aI., 1998). In addition to a decrease 
9 
in N- and O-acetyltransferase activity, there is also decreased protein level (Zhu and 
Hein, 2007). The R 187Q substitution is believed to interfere with the ability of the NAT1 
protein to be acetylated, therefore NAT1 14B is unstable, ubiquitinated, and then 
degraded by the 26 S proteasome (Butcher et aI., 2004). 
NA T1 *148 is associated with an increased risk of smoking-induced lung cancer. 
The OR for smoking induced lung cancer was 4.0 (95% confidence interval 0.8-19.6) for 
homozygous rapid (NA T1 *4 or NA T1 *3) acetylators, whereas the risk was found to be 
11.0 (95% confidence interval 1.3-106.5) for heterozygous slow (NAT1*148 or 
NA T1 *15) acetylators (Bouchardy et aI., 1998) compared to non-smokers. NA T1 *148 is 
present at low frequencies in many populations with the exception of the Lebanese 
population where the NA T1 *148 allelic frequency was reported to be 23.8% (Ohaini and 
Levy, 2000). 
NAT1*1O 
NA T1 *10 is characterized by two SNPs located in the region 3' to the open 
reading frame including T1088A and C1095A. There are no amino acid changes due to 
the polymorphisms, but the T1088A causes a change in the second potential 
polyadenylation signal (ATTAAA). The signal is not destroyed, but it is shifted 3' three 
nucleotides. It has been speculated that this change in polyadenylation signal may give 
rise to a difference in mRNA stability and modulated acetylation activity of NAT1 10 (Bell 
etal.,1995a). 
NA T1 *10 is putatively considered to be a rapid acetylator, however there are 
many conflicting results about the acetylator phenotype of NA T1 *10. Bell et al. reported 
significantly higher enzyme activity in urinary bladder and colon tissue for individuals 
heterozygous for NA T1 *10/1 *4 compared to those individuals homozygous for NA T1 *4. 
Similar findings were reported in colorectal tissue. In contrast, another study employing 
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recombinantly expressed alleles reported no difference between NAT1 10 and NAT1 4 
activities (de Leon et aI., 2000). 
NA T1 *10 is of great interest because it has been associated with increased risk 
of so many different forms of cancer, however the molecular contribution remains 
unclear. Specifically, NAT1*10 heterozygous genotype is associated with an odds ratio 
(OR) of 1.60 for non-Hodgkin lymphoma (Morton et aI., 2006), an OR of 2.2 for gastric 
adenocarcinoma (Boissy et aI., 2000), and an OR of 2.17 for prostate cancer (Hein et aI., 
2002) when compared to the homozygous NA T1 *4 genotype. It is clear that cancer risk 
associated with NA T1 *10 is further modulated by exposure to environmental 
carcinogens found in cigarette smoke, meats cooked at high temperatures, and hair dye. 
Frequent consumption of red meat in combination with the NA T1 *10 allele is associated 
with increased risk for colorectal cancer (Lilla et aI., 2006). The use of dark, permanent 
hair dye in combination with NA T1 *10 increases the risk for non-Hodgkin lymphoma 
(Morton et aI., 2007). Heavy smokers possessing the NAT1*10 allele have increased 
risk for pancreatic cancer compared to non-smokers (Li et aI., 2006) and an as well as 
increased risk for breast cancer (Zheng et aI., 1999). 
Although the contribution of NA T1 *10 to increased cancer risk is not well 
understood, molecular epidemiological studies have given us some clues. This study 
focuses on the association between cancer risk and the combination of NA T1 *10 and 
exposure to amine carcinogens. It is imperative that the phenotype of NAT1*10 be 
clearly defined in order to understand the association of NA T1 *10 genotype with 
increased cancer risk. 
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DNA Repair Deficient Chinese Hamster Ovary Cells 
The experiments described in this dissertation employ a strain of Chinese 
hamster ovary (CHO) cells referred to as UV5 cells that are deficient in the DNA 
nucleotide excision repair (NER) pathway. UV5 cells are deficient in transcription factor 
IIH (TFIIH), a multisubunit protein complex required for both transcription catalyzed by 
RNA polymerase II and NER (Drapkin et aL, 1994). Specifically, UV5 cells have a 
mutation in ERCC2 which is linked to excision repair deficiency and results in the genetic 
disease xeroderma pigmentosum group D (XPD) (Schaeffer et aL, 1994). This cell line 
is used to detect endpoints caused by mutagenesis and adduct formation because bulky 
adduct removal is compromised. This cell line was chosen to facilitate studying the 
genotoxic effects of aromatic amines due to metabolism by cytochrome p450 and NA T1 
alleles. In addition to NER deficiency, the UV5 cell line is commonly used because of its 
robust growth, ease in mutagenesis studies, and its ability to be transfected without 
affecting plating efficiencies (Li et aL, 1987). 
The UV5 cells that are employed in this study have been stably transfected with 
human cytochrome p450 (CYP1A1). This cell line allows genotoxic effects to be studied 
that require metabolic activation by CYP1A1 and NAT1. UV5 cells expressing CYP1A2 
and various NAT2 alleles have been used to compare the genotoxic effects of PhlP and 
MelQx (8endaly et aL, 2007; Metry et aL, 2007;). The experiments described in this 
dissertation express human CYP1A1 because, like human NAT1, it is expressed 
extrahepatically. These experiments employed NER-deficient CHO cells expressing 
human CYP1 A 1 and various NA T1 alleles to compare NA T1 polymorphism effects on 
aromatic amine metabolism, DNA adduct formation and mutation frequency. 
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4-amincbiphenyl 
This study uses the arcmatic amine 4-amicbiphenyl (ASP). ASP is a ccmmcn 
envircnmental carcincgen and a pctent bladder carcincgen (IARC, 1987). NA T1 is 
expressed extrahepatically, including bladder tissue (Sadawi et aI., 1995), therefcre, 
NA T1 metabclism is likely impcrtant fcr ASP-induced bladder cancer. 
ASP was widely used as an anticxidant in the rubber industry (IARC, 1987). 
Once its carcincgenic properties were disccvered, it was strictly prohibited by federal 
regulaticn. Hcwever, ASP can still be fcund as a ccntaminant in cclcr additives, paints, 
fccd cclcrs, leather, textile dyes, diesel-exhaust particles, cccking cil fumes and 
ccmmercial hair dyes (Nauwelaers et aI., 2011). ASP is also. still fcund in the aluminum 
industry (Guzzo. et aI., 2008). Cigarette smcke is a majcr scurce cf ASP expcsure. 
Mainstream smcke has been repcrted to. ccntain up to. 23 ng per cigarette and 
sidestream smcke has been repcrted to. ccntain up to. 140 ng per cigarette (Hcffmann et 
aI., 1997). Fcllcwing expcsure, ASP is metabclized in the liver by N-acetylaticn, N-
glucurcnidaticn, cr hydroxylaticn (Seyler et aI., 2010). Hemcglcbin (Hb) adducts have 
been repcrted to. be 75.8 pg/g Hb (66.5-86.5) in smckers and 29.9 pg/g Hb (24.7-36.2) in 
ncnsmckers (Seyler et aI., 2010). 
Flp-In System™ 
To. create a mcdel system to. investigate the carcincgenic effect cf ASP expcsure 
with different NAT1 alleles, Invitrcgen's Flp_ln™ System was used to. create a CHO cell 
line stably expressing a single ccpy cf NAT1. The Flp_ln™ system utilizes a 
Saccharcmyces cerevisiae-derived DNA reccmbinaticn system. NAT1 was integrated 
into. a specific site in the CHO gencme by a reccmbinase (Flp) and site-specific 
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recombination (Craig, 1988; Sauer, 1994). The NA T1 alleles were cloned into an 
expression vector, the pcDNA5/FRT (Figure 1-5) which utilizes the CMV promoter to 
drive constitutive expression of NA T1. The pcDNA5/FRT expression vector was co-
transfected with the pOG44 vector, which constitutively expresses the Flp recombinase. 
Figure 1-5: pcDNA5/FRT Expression Vector 
The pcDNA5/FRT is the chosen expression vector into which the 
NA T1 DNA was ligated. The polyadenylation signal was removed 
prior to ligation of NA T1 DNA. The vector contains one FRT site 
which allows it to be stably integrated into the CHO cell genome. 
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SPECIFIC AIMS 
Specific Aim I 
Create pcDNA5/FRT vector constructs which contain the human NA T1 alleles 
including NATa and NATb 5'-UTR exons, the open reading frame, and 885 base pairs of 
the region 3' to the open reading frame (with 6 potential polyadenylation signals). In 
addition to the reference NA T1 *4, constructs containing individual or combinations of 
genetic polymorphisms present in NA T1 *10, NA T1 *11, and NA T1 *14 will be constructed. 
Specific Aim II 
Prepare and characterize nucleotide excision repair deficient Chinese hamster 
ovary cells expressing human CYP1A1 transfected with pcDNA5/FRT vectors containing 
human NA T1 constructs. The functional effects of genetic polymorphisms in NA T1 *10, 
NA T1 *11, and NA T1 *14 will be compared to the reference allele NA T1 *4 in transient 
transfection experiments. Functional assays will include determinations of N- and 0-
acetylation catalytic activities (HPLC assays), mRNA levels (Taqman assays) and 
protein levels (Western blot assays). 
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Specific Aim III 
Test effects of NAT1 polymorph isms in stable CHO cell transfectants after 
exposure to various aromatic and heterocyclic amine carcinogens on levels of covalent 
DNA adduct formation (liquid chromatography-mass spectrometry assays) and 
mutagenicity (hprt mutants). 
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CHAPTER 2 
NATbINAT1*4 PROMOTES GREATER ARYLAMINE N-
ACETYL TRANSFERASE 1 MEDIATED DNA ADDUCTS AND MUTATIONS 
THAN NATaINAT1*4 FOLLOWING EXPOSURE TO 4-AMINOBIPHENYL 
INTRODUCTION 
Human arylamine N-acetyltransferase 1 (NAT1) is a phase II cytosolic enzyme 
responsible for the biotransformation of many arylamine compounds including 
pharmaceuticals and environmental carcinogens. A common environmental carcinogen 
found in cigarette smoke is an aromatic amine, 4-aminobiphenyl (ASP) (Internation 
Agency for Research on Cancer, 1987). Arylamines such as ASP can be inactivated via 
N-acetylation (Hein et aI., 1993). However, if ASP is first hydroxylated by cytochrome 
p4501A1 (CYP1A1), the hydroxyl-ASP then can be further activated by NAT1-catalyzed 
O-acetylation resulting in N-acetoxy-ASP (Hein et aI., 1993). This compound is very 
unstable and spontaneously degrades to form a nitrenium ion that can react with DNA to 
produce bulky adducts. If these adducts are not repaired, mutagenesis can occur and 
result in cancer initiation. 
The only known endogenous NAT1 substrate is p-aminobenzoylglutamate (PASG), 
a catabolite of folate (Wakefield et aI., 2007). NAT1 has been associated with various 
birth defects (Jensen et aI., 2005; Lammer et aI., 2004) that may be related to 
deficiencies in folate metabolism. NA T1 polymorphisms and maternal smoking have 
been associated with increased incidence of oral clefts, spina bifidia and increased limb 
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deficiency defects (Carmichael et aI. , 2006; Jensen et aI. , 2006). NAT1 polymorph isms 
have also been associated with increased risk for breast (Ambrosone et aI. , 2007; 
Millikan et aI. , 1998), pancreatic (Li et aI. , 2006; Suzuki et aI., 2008), urinary bladder 
(Gago-Dominguez et aI. , 2003; Sanderson et aI., 2007) and colorectal cancers (8ell et 
aI. , 1995a; Shin et aI. , 2008) , non-Hodgkin lymphoma (Kilfoy et aI. , 2010; Morton et aI. , 
2006), mammary cell growth (Adam et aI. , 2003) and breast cancer survival (Ring et aI. , 
2006). However, other studies have concluded that NAT1 polymorphism status is not 
associated with increased risk to bladder, esophageal , prostate or gastric cancers (Kidd 
et aI. , 2011 ; McGrath et aI. , 2006; Wideroff et aI. , 2007). NAT1 has also been implicated 
in cell growth and survival. Studies have shown that overexpression of NAT1 increased 
density dependent cell proliferation, and knock-down of NAT1 resulted in marked 
change in cell morphology, an increase in cell-cell contact inhibition and a loss of cell 
viability at confluence (Adam et aI. , 2003; Tiang et aI. , 2011). NA T1 *4 is referred to as 
the referent allele because it was the most common allele in the population in which it 
was first identified (Vats is and Weber, 1993). To date, 26 human NAT1 alleles have 
been identified (http://iouisville .edu/medschool/pharmacology/consensus-human-
arylamine-n-acetyltransferase-gene-nomenclature/). Although the effects of NAT1 
polymorphisms on catalytic activity have been studied, the results are ambiguous. 
Within single NAT1 genotypes, conflicting phenotypes have been reported , and the 
relationship between phenotype and genotype remains poorly understood. Since factors 
other than genotype are likely affecting phenotype, it is important to understand 
transcriptional and translational control of NA T1. 
The NAT1 gene spans 53 kb and contains nine exons (Figure 2-1a). Several NAT1 
transcripts have been identified containing various combinations of 5'-untranslated 
region (UTR) exons and are known to originate from two distinct promoters, NATa and 
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NATb. NATb, the major promoter, is located 11.8 kb upstream of the open reading 
frame (ORF). NATb promotes transcription of Type II transcripts and the major 
transcript, Type riA, has been detected in all tissues studied to date (Boukouvala and 
Sim, 2005; Husain et aI., 2004). An alternative promoter, NATa, originates 51.5 kb 
upstream of the NA T1 ORF and promotes transcription of Type I transcripts expressed 
primarily in kidney, lung, liver, and trachea (Barker et aI., 2006; Boukouvala and Sim, 
2005). The NAT1 gene is induced following exposure to androgens and NAT1 protein 
stability is affected by the presence of substrates (Minchin et aI., 2007). 
Recent analyses of genome-wide Pol II distribution in Drosophila and mammalian 
systems have reported that regulation of many genes occurs after transcription initiation 
(Aida et aI., 2006; Nechaev et aI., 2010) providing evidence for regulatory control in the 
5'-UTR that is distinct from promoter regulatory control. Recent studies have shown that 
between 30-50% of all human genes utilize alternative promoters (Cooper et aI., 2006; 
Takeda et aI., 2007) to allow for cell, tissue and disease specific expression. To 
determine if differences in 5'-UTR have functional effect upon NAT1 activity, DNA 
adducts or mutations following exposure to ABP, pcDNA5/FRT plasmid constructs were 
prepared for transfection of full length human mRNAs including the 5'-UTR derived from 
NATa or NATb, the NA T1 *4 open reading frame, and 888 nucleotides of the 3'-UTR. 
The constructs were cloned into two expression vectors utilizing two different constitutive 
promoters, (CMV and the EF1a promoters) to examine regulatory control located in the 
5'-UTR. The cells transfected with NATa/NAT1*4 and NATb/NAT1*4 constructs were 
characterized for NAT1 mRNA and protein expression, N- and O-acetyltransferase 
activity (in vitro and in situ), ABP-induced DNA adducts and hypoxanthine 
phosphoribosy/ transferase (hprt) mutations following exposure to ABP. 
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METHODS 
Polyadenylation Site Removal 
The bovine growth hormone (BGH) polyadenylation site from the pcDNA5/FRT 
(Invitrogen, Carlsbad, CA) vector was removed to allow the endogenous NA T1 
polyadenylation sites to be active. This was accomplished by digestion at 37°C with 
restriction endonucleases, Apal and Sphl (New England Biolabs, Ipswich, MA), followed 
by overhang digestion with T4 DNA polymerase (Invitrogen) and ligation with T4 Ligase 
(Invitrogen). 
NATb/NA T1*4 and NATalNA T1*4 Constructs 
NATb/NAT1*4 and NATalNA T1*4 constructs were created utilizing gene splicing via 
overlap extension (Horton et aL, 1989) by amplifying the 5'-UTR and the coding 
region/3'-UTR separately and then fusing the two regions together. Beginning with 
frequently used transcription start sites, the 5'-UTRs (Barker et aL, 2006; Husain et aL, 
2004) were amplified from cDNA prepared from RNA isolated from homozygous NAT1*4 
HepG2 cells. All primer sequences used are shown in Table 1. The primers used to 
amplify the NATb 5'-UTR region were Lkm40P1 and NAT1 (3') ORF Rev while the 
primers used to amplify the NATa 5'-UTR region were Lkm41P1 and NAT1 (3') ORF 
Rev. The coding region and 3' -UTR were amplified as one piece from NA T1 *4 human 
genomic DNA with NA T1 *4INA T1 *4 genotype. The forward primer used to amplify the 
coding region/3'-UTR was NAT1 (3') ORF Forward while the reverse primer was 
pcDNA5distai Reverse. The two sections, the 5'-UTR and the coding region/3'UTR, were 
fused together via overlap extention and amplification of the entire product using nested 
primers. The forward nested primer for NATb was P1 Fwd Inr Nhel while the forward 
nested primer for NATa was P3 Fwd Inr Nhel. The reverse nested primer for both NATa 
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and NATb constructs was NAT1 Kpn Rev. Both forward nested primers included the 
Kpnl endonuclease restriction site and both reverse nested primers contained the Nhel 
endonuclease restriction site to facilitate cloning. The pcDNA5/FRT vector and 
NATa/NAT1*4 and NATbINAT1*4 allelic segments were digested at 37°C with restriction 
endonucleases Kpnl and Nhel (New England Biolabs). The NA T1 constructs were then 
ligated into pcDNA5/FRT using T4 ligase (Invitrogen). These same NAT1 constructs 
were also cloned into a second expression vector, pEF1/5V-His (Invitrogen). The 
NATblNA T1*4 construct was amplified using the forward primer, NATb Forward pEF1, 
while the NATalNAT1 *4 construct was amplified using the forward primer NATa Forward 
pEF1. Both forward primers contained the BamHI restriction site. Both constructs were 
amplified using the reverse primer NATa/b Reverse pEF1 which contained the EcoRV 
restriction site. Both NATalNAT1 *4 and NATbINAT1*4 and pEF1/5V-His were digested 
with the restriction endonucleases, BamHI and EcoRV (New England Biolabs), followed 
by ligation into the vector using T4 ligase (Invitrogen). All constructs were sequenced to 
ensure integrity of allelic segments and junction sites. 
Cell Culture 
UV5-CHO cells, a nuclease excision repair (NER)-deficient derivative of AA8 which 
are hypersensitive to bulky DNA lesions, were obtained from the ATCC (catalog number: 
CRL-1865). Unless otherwise noted, cells were incubated at 37DC in 5% CO2 in 
complete alpha-modified minimal essential medium (a-MEM, Lanza, Walkersville, MD) 
without L-glutamine, ribosides, and deoxyribosides supplemented with 10% fetal bovine 
serum (Hyclone, Logan, UT), 100 units/mL penicillin (Lanza), 100 IJg/mL streptomycin 
(Lanza), and 2 mM L-glutamine (Lanza). The UV5/CHO cells used in this study were 
previously stably transfected with a single Flp Recombination Target (FRT) integration 
site (Metry et aI., 2007). The FRT site allowed stable transfecions to utilize the Flp-In 
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System (Invitrogen). When co-transfected with pOG44 (Invitrogen), a Flp recombinase 
expression plasmid, a site-specific, conserved recombination event of pcDNA5/FRT 
(containing either NATalNAT1 *4 or NATblNA T1 *4) occurs at the FRT site. The FRT site 
allows recombination to occur immediately downstream of the hygromycin resistance 
gene, allowing for hygromycin selectivity only after Flp-recombinase mediated 
integration. The UV5/FRT cells were further modified by stable integration of human 
CYP1A1 and NADPH-cytochrome P450 reductase gene (POR) (Metry et aI., 2007). 
They are referred to in this manuscript as UV511A1 cells. 
Transient Transfection 
UV511A1 cells were transiently transfected with pcDNA5/FRT (Invitrogen) or 
pEF1 N5-His (Invitrogen) containing NATalNA T1 *4 and NATblNA T1 *4 constructs using 
Lipofectamine reagent (Invitrogen) following the manufacturer's recommendations. 
UV5/1A 1 cells were co-transfected with pCMV-SPORT-J3gal (J3-galactosidase 
transfection control plasmid, Invitrogen). The cells were harvested the next day. Lysate 
was prepared by centrifuging the cells and resuspending pellet in homogenization buffer 
(20 mM NaP04 pH 7.4, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 2 jJg/mL aprotinin and 
2 mM pepstatin A). The resuspended cell pellet was subjected to 3 rounds of freezing at 
-80°C and thawing at 37°C and then centrifuged at 15,000xg for 10 min. The 
supernatant was used to measure N-acetyltransferase activity and J3-galactosidase 
activity. 
Stable Transfections 
Stable transfections were carried out using the Flp-In System (Invitrogen) into 
UV511A 1 cells that were previously stably transfected with a FRT site (as noted above). 
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The pcDNAS/FRT plasm ids containing human NATa/NA T1 *4 or NATb/NAT1*4 were co-
transfected with pOG44 (Invitrogen), a Flp recombinase expression plasmid. UVS/1A1 
cells were stably transfected with pcDNAS/FRT containing NATa/NA T1 *4 and 
NATb/NA T1*4 constructs using Effectene transfection reagent (Qiagen, Valencia, CA) 
following the manufacturer's recommendations. Since the pcDNAS/FRT vector contains 
a hygromycin resistance cassette, cells were passaged in complete a-MEM containing 
600 ~g/mL hygromycin (Invitrogen) to select for cells containing the pcDNAS/FRT 
plasmid. Hygromycin resistant colonies were selected approximately 10 days after 
transfection and isolated with cloning cylinders. 
Measurement of N-Acetyltransferase Enzymatic Activity 
In vitro assays using the NAT1 specific substrate para-aminobenzoic acid (PABA) or 
4-aminobiphenyl (ABP) were conducted and acetylated products were separated 
utilizing HPLC (Hein et aI., 2006). Reactions containing SO ~L cell lysate, PABA or ABP 
(300 ~M) and acetyl coenzyme A (1 mM) were incubated at 3TC for 10 min. Reactions 
were terminated by the addition of 1/10 volume of 1 M acetic acid and centrifuged at 
1S,000Xg for 10 min. Supernatant was injected into a (12S mm X 4 mm; S ~M pore size) 
reverse phase C18 column. Reactants and products were eluted using a Beckman 
System Gold high performance liquid chromatograph (HPLC) system. HPLC separation 
of N-acetyl-PABA was achieved using a gradient of 96:4 sodium perchlorate pH 
2.S:acetonitrile (ACN) to 88:12 sodium perchlorate pH 2.S: ACN over 3 min and was 
quantitated by absorbance at 280 nm. HPLC separation of N-acetyl-ABP was achieved 
using a gradient of 8S:1S sodium perchlorate pH 2.S:ACN to 3S:6S sodium perchlorate 
pH 2.S:ACN over 10 min and was quantitated by absorbance at 260 nm. Measurements 
were adjusted according to baseline measurements using Iysates of the UVS/CYP1 A 1 
cell line. Both stably and transiently transfected cells were normalized by the amount of 
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total protein. Assays involving transiently transfected cells and PABA used [3-
galactosidase activity to control for transfection efficiency. To correct for transfection 
efficiency, [3-galactosidase plasm ids (pCMV-sport-[3gal) were co-transfected with 
pcDNA5/FRT or pEF1/5V-His. [3-galactosidase activity was measured in reactions 
containing 30 IJL cell lysate, 70 IJL of 4 mg/mL ortho-nitrophenyl-[3-D-galactopyranoside 
(ONPG), and 200 IJL of cleavage buffer (60 mM Na2HP04, 40 mM NaH2P04, and 1 mM 
MgS04, pH 7.0). The reaction was incubated for 30 min at 3rC. The reaction was 
terminated by the addition of 500 IJL of 1 M sodium carbonate and absorbance at 420 
nm was measured. Protein concentrations were measured using the method of 
Bradford (Bio-Rad, Hercules, CA). The [3-galactosidase activities were normalized to 
total protein and the resulting values were used to correct for the effect of any 
differences in transfection efficiency. In situ N-acetyltransferase activity was studied in a 
whole cell assay using media spiked with differing concentrations of PABA (10 - 300 
IJM). The cells were incubated at 37°C and media was collected after 5 h, 1/10 volume 
of 1 M acetic acid was added, and the mixture was centrifuged at 13,000xg for 10 min. 
The supernatant was injected into the reverse phase HPLC column and N-acetyl-PABA 
was separated and quantitated as described above. 
Measurement of O-Acetyltransferase Enzymatic Activity 
N-hydroxy-4-aminobiphenyl (N-OH-ABP) O-acetyltransferase assays were 
conducted as previously described (Metry et aI., 2007). Assays containing 100 IJg total 
protein, 1 mM acetyl coenzyme A, 1 mg/mL deoxyguanosine (dG), and 100 IJM N-OH-
ABP were incubated at 37°C for 10 min. Reactions were stopped with the addition of 
100 IJL of water saturated ethyl acetate and centrifuged at 13,000xg for 10 min. The 
organic phase was removed, evaporated to dryness and the residue was dissolved in 
100 IJL of 10% ACN. HPLC separation was achieved using a gradient of 80:20 sodium 
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perchlorate pH 2.5:ACN to 50:50 sodium perchlorate pH 2.5:ACN over 3 min and dG-
C8-ABP adduct was detected at 300 nm. 
Measurement of NAT1 Protein 
The amount of NAT1 produced in UV511A1 cells stably transfected with 
NATalNA T1 *4 or NATblNA T1 *4 was determined by western blot. Ceillysates were 
isolated as described above. Varying amounts of lysate were mixed 1: 1 with 5% 13-
mercaptoethanol in Laemmli buffer (Bio-Rad), boiled for 5 min, and resolved by 12% 
SDS-PAGE. The proteins were then transferred by semi-dry electroblotting to 
polyvinylidene fluoride (PVDF) membranes. The membranes were probed with a 
polyclonal rabbit anti-hNAT1 ES195 (1:1000) kindly provided by Edith Sim (Stanley et 
aI., 1996) and with horseradish peroxidase (HRP)-conjugated secondary goat anti-rabbit 
IgG antibody (1 :20,000) (Pierce, Rockford, IL). Supersignal West Pico 
Chemiluminescent Substrate was used for detection (Pierce) and densitometric analysis 
was performed using Quantity One Software (Bio-Rad). 
Measurement of NAT1 mRNA 
Total RNA was isolated from cells using the RNeasy kit (Qiagen) followed by 
removal of contaminating DNA by treatment with TurboDNase Free (Ambion, Austin, 
TX). Synthesis of cDNA was performed using qScript cDNA Synthesis Kit (Quanta 
Biosciences, Gaithersburg, MD) using 1 I-Ig of total RNA in a 20 I-IL reaction per the 
manufacturer's protocol. Quantitative RT-PCR (RT-qPCR) assays were used to assess 
the relative amount of NA T1 mRNA in cells stably transfected with NATalNA T1 *4 
compared to cells stably transfected with NATbINAT1*4. The Step One Plus (Applied 
Biosystems, Foster City, CA) was used to perform qRT-PCR in reactions containing 1x 
final concentration of qScript One-Step Fast mix (Quanta Biosciences), 300 nM of each 
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primer and 100 nM of probe in a total volume of 20 IJL. For qRT -PCR of NA T1 mRNA, a 
TaqMan probe was used with NAT1 Total Splice Forward and NAT1 Total Splice 
Reverse primers (Table 1) designed using Primer Express 1.5 software (Applied 
Biosystems). An initial incubation at 50°C was carried out for 2 min and at 94°C for 10 
min followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. TaqMan® 
Ribosomal RNA Control Reagents for quantitation of the endogenous control, 18S rRNA, 
(Applied Biosystems) were used to determine ~Ct (NA T1 Ct -18S rRNA Ct). ~~Ct was 
determined by subtraction of the smallest ~Ct and relative amounts of NA T1 mRNA 
were calculated using 2-MC1 as previously described (Barker et aI., 2006). 
Measurement of NAT1 mRNA Stability 
Dishes (100 x 20 mm) containing 8 x 106 stably transfected NATaINAT1*4 and 
NATblNA T1 *4 cells were treated with complete a-MEM media spiked with 10 ug/mL of 
the transcription inhibitor, Actinomycin D (Sigma, St. Louis, MO). Cells were collected at 
0, 2, 4, 6, and 8 hour time points and total RNA was isolated as described above. 
Relative NAT1 mRNA levels were determined from cells transfected with NATaINAT1*4 
or NATblNA T1*4 utilizing qRT-PCR assays as described above. The first-order rate 
decay constant (slope) of NA T1 mRNA was determined by linear regression. 
DNA Isolation and dG-C8-ABP Quantitation 
DNA was isolated and dG-C8-ABP adducts were quantitated with modifications to a 
previously described method (Metry et aI., 2007). Cells grown to approximately 80% 
confluency in 15 cm dishes were incubated in complete a-MEM media containing 1.56, 
3.13,6.25,12.5 IJM ABP or vehicle alone (0.5% DMSO) at 37°C. The cells were 
collected following 24 h of treatment, centrifuged for 5 min at 13,OOOxg, and the pellet 
was resuspended in 2 volumes of homogenization buffer (20 mM sodium phosphate pH 
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7.4, 1 mM EDT A), 0.1 volumes of 10% SDS and 0.1 volume of 20 mg/mL Proteinase K 
and allowed to incubate overnight at 37nC. The DNA was extracted using 
phenol/chloroform:isoamyl alcohol and precipitated with isopropanol. The pellet was 
dried and resuspended in 500 j.JL of DNA adduct buffer (5 mM Tris pH 7.4, 1 mM CaCI2, 
1 mM ZnCb, and 10 mM MgCI2). The DNA was quantitated by spectrophotometry at 
A260. Five hundred pg of internal standard (dG-C8-ABP-d5, Toronto Research 
Chemicals, North York, Ontario, Canada) was added to 30 j.Jg of sample DNA, treated 
with 10 units DNase I (US Biological, Swampscott, MA) for 1 h at 37°C followed by 
treatment with 10 units nuclease P1 (Sigma) for 6 h. The reactions were then treated 
with 10 units of alkaline phosphatase (Sigma) overnight at 37°C. The samples were 
then loaded onto PepClean C-18 Spin Columns (Thermo Fisher Scientific), washed with 
10% acetonitrile (ACN), eluted with 50% ACN by centrifugation at 2000xg and dried. 
The samples were reconstituted with 25 j.JL 5% ACN in 2.5 mM NH4HC03 just before 
analysis and 10 j.JL of the sample was analyzed by Accela LC System (Thermo 
Scientific, San Jose, CA) coupled with a L TQ-Orbitrap XL mass spectrometer (Thermo 
Scientific, San Jose, CA). Samples were loaded onto a 30 x 1 mm x 1.9 j.Jm Hypersil 
GOLD column (Thermo Scientific, San Jose, CA) and eluted with a 12.5 minute binary 
solvent gradient (Solvent A: 5% ACN/0.1 % formic acid and Solvent B: 95% ACN/0.1 % 
formic acid) at 50 j.Jl/min. The gradient started from 5% Solvent B, increased linearly to 
75% Solvent B in 10 min, and then remained at 75% B for 2.5 min. The eluates were 
ionized by electrospray isonization and dG-C8-ABP and dG-C8-ABP-d5 were detected 
with linear ion trap and detected by multiple reaction monitoring using the transitions of 
m/z 435.2 to m/z 319.2 (dG-C8-ABP) and m/z 440.2 to m/z 324.2 (dG-C8-ABP-d5). 
Concentrations of dG-C8-ABP were calculated from peak areas of dG-C8-ABP and dG-
C8-ABP-d5 with a calibration curve from synthetic dG-C8-ABP and dG-C8-ABP-d5. 
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Measurement of Cytotoxicity and Mutagenesis 
Assays for cell cytoxicity and mutagenesis were carried as previously described 0Nu 
et aI., 1997) with slight modifications. Cells were grown in HAT medium (30 mM 
hypoxanthine, 0.1 mM aminopterin, and 30 mM thymidine) for 12 doublings. Cells 
(1x106) were plated, allowed to grow for 24 h and were then treated with 1.56,3.13,6.25 
or 12.5 !-1M ASP (Sigma) or vehicle alone (0.5% DMSO) in media. After 48 h, cells were 
plated to determine survival and mutagenic response to ASP. To determine cloning 
efficiency following each dose of ASP, 100 cells were plated in triplicate in 6 well-plates 
and allowed to grow for 7 days in non-selective media. Colonies were counted and 
expressed as percent of vehicle control. To determine mutagenic response following 
ASP exposure, 5x1 05 cells were plated and sub-cultured for 7 days and then seeded 
with 1x105 cells/100 x 20 mm dish (10 replicates) in complete aMEM containing 40 mM 
6-thioguanine (Sigma). Mutant hprt cells were allowed to grow for 7 days and colonies 
were counted to determine ASP-induced mutants and corrected by cloning efficiency. 
Statistical Analysis 
Statistical differences were determined using either an unpaired student's t-test or 
one-way ANOVA using Prism Software by Graphpad (La Jolla, CA). 
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RESULTS 
PABA N-Acetylation Following Transfection of NATb/NAT1 *4 or NATaINAT1*4 
PABA N-acetylation activity was 9- to 12-fold (p<O.05) higher in CHO cells 
transfected with NATb/NAT1*4 than NATa/NAT1*4 following both transient and stable 
transfections (Figure 2-2 a,b) utilizing the CMV promoter. Figure 2-2b shows average 
PABA N-acetylation for 3 stable clones of each NATb/NA T1*4 and NATalNA T1 *4. One 
clone representative was selected from each group to conduct all further assays. To 
ensure that the difference was not promoter specific, N-acetylation activity was also 
measured following transfection with constructs utilizing the EF1a promoter. PABA N-
acetylation activity was 6-fold (p<O.0001) higher in CHO cells transiently transfected with 
NATb/NA T1 *4 than NATalNA T1 *4 (Figure 2-2c) utilizing the EF1 a promoter. To more 
accurately model in vivo N-acetylation and to confirm the in vitro results, an in situ assay 
was performed using PABA as the substrate in a dose response experiment (Figure 2-
2d). The in situ assay showed that significantly (p<O.05) more PABA N-acetylation 
activity was observed in cells stably transfected with NATb/NAT1*4 than NATa/NA T1*4 
at all concentrations tested (Figure 2-2d) utilizing the CMV promoter. As shown in figure 
2-3, PABA N-acetylation activity also was significantly higher in COS-1 cells transiently 
transfected with NATb/NA T1 *4 than with NATalNA T1 *4 utilizing either the CMV 
(p<O.005) or EF1a (p<O.0001) promoters. 
ABP N-Acetylation and N-hydroxy-ABP O-acetylation Following Transfection of 
NATb/NAT1*4 or NATaINAT1*4 
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Cells stably transfected with NATblNA T1 *4 were found to have 7 -fold (p<0.0001) 
higher ABP N-acetylation activity than cells stably transfected with NATalNA T1 *4 (Figure 
2-4a) utilizing the CMV promoter. O-acetyltransferase activity using N-OH-ABP as the 
substrate also was found to be 7-fold (p<0.05) higher in cells stably transfected with 
NATbINAT1*4 than NATa/NAT1*4 (Figure 2-4b) utilizing CMV promoter. 
Expression of NAT1 Protein Following Transfection of NATbINAT1*4 or NATaINAT1*4 
NAT1 expression was determined by western blot in cells stably transfected with 
NATbINAT1*4 and NATa/NAT1*4 utilizing the CMV promoter. Four-fold (p<0.05) more 
NAT1 was found in cells stably transfected with NATbINAT1*4 than cells transfected 
with NATa/NA T1 *4 following densitometric analysis (Figure 2-5). 
Expression of NAT1 mRNA Following Transfection of NATblNA T1*4 or NATaINAT1*4 
As shown in Figure 2-6a, 4-fold more NAT1 mRNA was detected in cells stably 
transfected with NATblNA T1*4 than in cells transfected with NATa/NAT1*4 (p<0.05) 
utilizing the CMV promoter. To determine the cause of the difference in NAT1 steady-
state mRNA between cells stably transfected with NATblNA T1 *4 and in cells transfected 
with NATa/NAT1*4, an mRNA stability assay was performed in the presence of 
actinomycin-D. No significant (p>0.05) difference in the NAT1 mRNA first-order decay 
constant was observed between NAT1 mRNA derived from cells stably transfected with 
NATblNA T1*4 versus NATa/NAT1*4 (Figure 2-6b). 
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Cytoxicity, dG-C8-ASP Adduct and hprt Mutations from ASP in UV5/1A 1 Cells Stably 
Transfected With NATb/NAT1*4 or NATa/NAT1*4 
CYP1A1 mediated hydroxylation and NAT1 O-acetylation result in DNA adducts and 
mutations, if not repaired. Significantly (p<O.05) greater cytoxicity (Figure 2-7a), dG-C8-
ASP adducts (Figure 2-7b) and hprt mutants (Figure 2-7c) were detected in cells stably 
transfected with NATb/NA T1*4 than NATalNAT1*4 utilizing the CMV promoter at each 
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Figure 2-1: Genomic Organization of NA T1 gene 
(a) Genomic organization of NAT1 gene; (b) Type IIA and Type IA NAT1 RNA (c) and 
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Figure 2-2: NATb and NATa N-acetylation of PABA 
* 
NATa 
10 50 100 200 
"MPABA 
N-acetylation of PABA in UV5/1A1 cells expressing CYP1A1 and NATbINAT1*4 (solid 
bars) or NATalNA T1*4 (open bars). (a) PABA N-acetylation activity following transient 
transfection with pcDNA5/FRT; (b) PABA NAT1 catalytic activity following stable 
transfection with pcDNA5/FRT of 3 different clones of each NATblNA T1 *4 and 
NATaINAT1*4; (c) PABA N-acetylation activity following transient transfection with 
pEF1N5-His; (d) PABA N-acetylation in situ following stable transfection of 
pcDNA5/FRT. Each bar represents mean ± S.E.M. for three transient transfections (a, 
c), 3 separate collections of 3 clones (b) or 3 separate collections of 1 clone (d). 
Asterisks (*) represent a significant difference (p<O.05) (a, b, d) or (p<O.0001) (c) 
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Figure 2-3: NATb and NATa N-acetylation of PABA in COS-1 cells 
N-acetylation of PABA in COS-1 cells transiently transfected with (a) pcDNAS/FRT or 
pEF1NS-His (b) containing NATb/NAT1*4 or NATa/NAT1*4. Each bar represents mean 
± S.E.M. for three transient transfections. Asterisks represent a significant difference 
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Figure 2-4: NATb and NATa N- and O-acetylation of ABP 
(a) N-acetylation of ASP and (b) O-acetylation of N-hydroxy-ASP in UV5/1A1 cells stably 
expressing CYP1A 1 and either NATblNA T1*4 (solid bars) or NATaINAT1*4 (open bars) 
in pcDNA5/FRT. Each bar represents mean ± S.E.M. for three separate collections. 
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Figure 2-5: NATb and NATa protein expression 
NAT1 protein expression in UVS/1 A 1 cells stably expressing CYP1 A 1 and 
NATb/NA T1*4 (solid bars) or NATa/NA T1*4 (open bars) in pcDNAS/FRT. (a) 
Representative western blot of 20 IJg of total protein loaded; (b) Percent intensity units 
(NATb defined as 100%) of densitometric analysis perfomed on three independent 
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Figure 2-6: NATb and NATa mRNA levels 
(a) NAT1 mRNA expression levels; (b) mRNA stability in UV5/1A1 cells stably 
expressing CYP1A 1 and NATbINAT1*4 (solid bars) or NATalNA T1*4 (open bars) in 
pcDNA5/FRT. Each bar represents mean ± S.E.M. for (a) three or (b) nine 
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Figure 2-7: ABP-induced cytoxicity, mutagenesis and DNA adducts 
ASP-induced cytotoxicity, mutagenesis, and DNA adduct formation in CHO cells stably 
expressing CYP1A1 only (triangles) and NATbINAT1*4 (circles) or NATaINAT1*4 
(squares) in pcDNA5/FRT. Each data point represents mean ± S.E.M. for three 
determinations. (a) ASP-induced cytotoxicity; (b) ASP-induced dG-C8-ASP adducts/108 
nucleosides; (c) ASP-induced hprt mutant levels. 
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DISCUSSION 
As outlined in the introduction, numerous studies report that NA T1 genetic 
polymorphisms increase cancer risk following exposure to heterocyclic and aromatic 
amines. Due to the large variability in NAT1 activity that has been reported within a 
single genotype, it is becoming increasingly more apparent that factors other than 
genetic polymorph isms are affecting gene expression and cancer risk. One such factor 
is the use of alternative promoters to produce mRNAs with distinct 5'-UTRs. Recent 
studies have shown that between 30-50% of all human genes utilize alternative 
promoters (Cooper et aI., 2006; Takeda et aI., 2007) to allow for cell, tissue and disease 
specific expression. NAT1 has two promoters, NATa and NATb, which differ in promoter 
strength and tissue specificity (Barker et aI., 2006; Husain et aI., 2007). Transcripts 
derived from NATa are found primarily in liver, lung, trachea and kidney, while 
transcripts derived from NATb are found in all tissues studied to date (Barker et aI., 
2006; Husain et aI., 2007). It is possible that NATa transcripts are expressed in a wider 
range of tissues, but only when the cell is under specific environmental stress or disease 
states. For example, expression of NATa transcripts has recently been reported in 
several ER-positive breast cancer cell lines (Wakefield et aI., 2008). NATa transcripts 
may be selectively up-regulated following certain environmental exposures or in specific 
tissues, such as breast, during certain disease states. 
In the current study, two referent NA T1 *4 constructs were cloned to mimic the most 
common transcripts originating from each of the two alternative NAT1 promoters, NATa 
and NATb (Figure 3-1a). Beginning with frequently used transcription start sites, the 
constructs include all exons found in the most common NA T1 transcripts originating at 
the NATa or NATb promoters and represent Type la or Type IIa transcripts (Barker et 
aI., 2006; Butcher et aI., 2005; Husain et aI., 2004). The NATa/NA T1*4 and 
39 
NATb/NAT1*4 constructs have identical open reading frames (ORFs) and 3'-UTRs. 80th 
constructs include the entire ORF comprised of 870 nucleotides and 888 nucleotides of 
the 3'-UTR. The only difference between the two constructs is the 5'-UTR. The NATb 5'-
UTR contains 117 nts and includes exon 4 and exon 8 while the NATa 5'-UTR contains 
371 nts and includes exons 1, 2, 3, and 8 (Figure 3-1 b, c). 
Two constitutive promoters, the CMV and the EF10 promoter, were used to drive 
transcription of either the NATb/NA T1 *4 or NATa/NA T1 *4 full length transcripts to 
examine regulatory control located in the 5'-UTRs. In this study, we report that cells 
transfected with NATb/NA T1 *4 had approximately 4-times greater NAT1 expression than 
cells transfected with NATa/NA T1 *4. A 4-fold difference in NAT1 mRNA expression also 
was observed, suggesting that transcriptional control is largely responsible for the 
functional differences observed between NATb/NA T1 *4 and NATa/NA T1 *4. Recent 
studies have elucidated a large number of tissue- and cell-type specific isoforms of 
transcription factors and cis-acting factors. Alternative 5'-UTRs contribute to this 
intricate control of transcription allowing for very specific altered expression in tissues, 
cells and even disease states (Davuluri et al., 2008). The differences we observed were 
not caused by a specific interaction between the promoter and one of the 5'-UTRs 
because results were confirmed using two different constitutive promoters, CMV and 
EF10. 
There are many regulatory mechanisms that could be responsible for the 
observed differences in expression and functional effects including polymerase pausing, 
microRNA binding, and the presence of upstream open reading frames and stem loops. 
A recent genome wide study has provided evidence that many genes are controlled after 
transcription initiation has occurred (Nechaev et aI., 2010) and another such study 
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reveals that polymerase pausing may be a widespread genetic control of gene 
expression (Core et aL, 2008). Elongation of transcription is known to be non-uniform 
and RNA polymerases are prone to transient pausing that is sequence dependent 
(Adelman et aL, 2002). Polymerase pausing could be examined in the NATa- and NATb-
transfected cell lines by nuclear run-on or RIP-chip assays. A second possible 
mechanism of regulation is microRNA (miRNA) binding which regulates gene expression 
by catalyzing mRNA cleavage (Ambros, 2004; Doench and Sharp, 2004). 
Microlnspector (miRNA target software) predicted only 2 miRNA binding sites in the 
NATb 5'-UTR located at positions 7 (has-miR-3937) and 46 (has-miR-198) while 54 
miRNA binding sites were predicted throughout the NATa 5'-UTR. Regulation by these 
miRNAs could be analyzed by such methods as northern hybridization or microarray 
analysis. A third possible mechanism is regulation by upstream open reading frames 
(uORFs) which have been shown to reduce protein and mRNA expression (Calvo et aL, 
2009). Both NATa and NATb 5'-UTRs were examined for uORFs by the NCB I ORF 
Finder. The NATa 5'-UTR was predicted to have 2 uORFs, while the NATb 5'-UTR was 
predicted to have none. Studies including a luciferase reporter assay could be 
conducted to determine the transcriptional effects on the NATa 5'-UTR due to uORFs. 
Lastly, differential regulation of the NATa and NATb 5'-UTRs could be due to the 
presence of stem-loops (Malys and McCarthy, 2011). NATa and NATb 5'-UTRs were 
both examined for the presence of stem-loops by OligoCalc (Northwestern University, 
Evanston, IL) with a constraint of 5 base pair minimum. The NATa 5'-UTR has 42 
potential stem-loop structures while the NATb 5'-UTR has only 7 potential stem-loop 
structures. Real time observation of transcription initiation and elongation (Larson et aL, 
2011) could be useful to determine the mechanism of the differential regulation observed 
between NATa and NATb 5'-UTRs. 
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Significantly more NAT1 activity, protein, mRNA, ABP-induced cytoxicity, DNA 
adducts and mutagenesis were detected in cells stably transfected with NATbINAT1*4 
than in cells transfected with NATaiNA T1*4 (p<0.05). DNA adduct and mutant levels 
following exposure to ABP are biological endpoints that are very relevant to cancer risk. 
The findings that ABP-mediated DNA adduct and mutant levels were significantly higher 
in cells transfected with elevated NAT1 catalytic activity emphasizes the relative 
importance of NAT1-catalyzed O-acetylation of N-hydroxy-ABP in cancer risk. 
Associations between higher N-acetyltransferase 2 catalytic activity with higher ABP-
mediated cytoxicity, DNA adduct formation, and mutagenesis also were recently 
reported (Bendaly et aI., 2009). The finding that these cancer risk indicators were higher 
in cells transfected with NA Tbl NA T1 *4 than cells transfected with NATal NA T1 *4 suggest 
that differential regulation in the NA T1 5'-UTR also may modify ABP-mediated cancer 
risk. Because NATb transcripts are expressed ubiquitously, the minor transcript, NATa, 
may be expressed following environmental exposures or under certain disease states 
resulting in increased mutagenesis, enhanced tumor growth, and decreased 
chemotherapeutic sensitivity. For example, expression of NATa transcripts have 
recently been reported in several ER-positive breast cancer cell lines (Wakefield et aI., 
2008). 
The findings of this study are significant due to their relevance to ABP-mediated 
carcinogenesis. However, translation of our results obtained in cell culture to human 
subjects will require additional studies to investigate tissue specificity. Although our 
study focused only on the referent allele, NA T1 *4, future studies should investigate 5'-
UTR control with other NA T1 alleles, particularly those associated with increased cancer 
risk. Future investigations to determine mechanism(s) and location(s) of the differential 
regulation in the NAT1 5'-UTR also are needed. 
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CHAPTER 3 
PHENOTYPE OF THE MOST COMMON "SLOW ACETYLA TOR" ARYLAMINE 
N-ACETYL TRANSFERASE 1 GENETIC VARIANT (NAT1*14B) IS SUBSTRATE 
DEPENDENT 
INTRODUCTION 
Human arylamine N-acetyltransferase 1 (NAT1) is a phase II cytosolic enzyme 
responsible for the biotransformation of many arylamine compounds including 
pharmaceuticals and environmental carcinogens (Hein et aI., 2000). NAT1 catalyzes 
both arylamine N-acetylation and O-acetylation. Genetic polymorphisms in NAT1 can 
alter the amount of NAT1 protein and result in modified enzymatic activity. In addition to 
bioactivation of arylamines, recent studies have provided evidence that NAT1 is involved 
in density dependent cell growth and survival. Studies have shown that overexpression 
of NAT1 increased density dependent cell proliferation, whereas knock-down of NAT1 
resulted in marked change in cell morphology, an increase in cell-cell contact inhibition 
and a loss of cell viability at confluence (Adam et aI., 2003; Tiang et aI., 2011). 
Molecular epidemiological studies have reported associations between NAT1 genetic 
polymorphisms and altered risk for developing several types of cancer including urinary 
bladder (Gago-Dominguez et aI., 2003), breast (Ambrosone et aI., 2007; Millikan et aI., 
1998; Zheng et aI., 1999), colorectal (8ell et aI., 1995b; Lilla et aI., 2006), lung (Wikman 
et aI., 2001), non-Hodgkin lymphoma (Morton et aI., 2006) and pancreatic (Li et aI., 
2006). The only known endogenous NAT1 substrate is p-aminobenzoylglutamate 
43 
(PABG), a catabolite of folate. late (Wakefield et aI., 2007). NA T1 has been associated 
with various birth defects (Jensen et aI., 2005; Lammer et aI., 2004) that may be related 
to deficiencies in folate metabolism. The most common NAT1 variant allele associated 
with reduced acetylator phenotype is NA T1 *148. The allelic frequency for NA T1 *14B in 
the Lebanese population was determined to be 23.8% (Ohaini and Levy, 2000). 
NA T1 *148 is likely to be very prevalent in other countries in the middle east, however 
allelic frequencies for many of those populations are not available. NA T1 *148 has been 
associated with an increased risk of smoking-induced lung cancer (Bouchardy et aI., 
1998). 
NA T1 *148 is characterized by a single nucleotide polymorphism (SNP) G560A 
(rs4986782) located in the open reading frame (ORF). G560A results in an amino acid 
substitution R1870. Computational homology modeling based on the NAT1 crystal 
structure indicate that the side chain of R 187 is partially exposed to the domain II beta 
barrel, the protein surface, and the active site pocket (Walraven et aI., 2008). 
Interactions with these domains serve to stabilize the protein and help shape the active 
site pocket. The substitution of arginine for glutamine results in at least partial loss of 
these stabilizing hydrogen bonds resulting in destabilization of the NAT1 structure. 
Therefore, homology modeling predicts that NAT1 binding of acetyl coenzyme A 
(AcCoA), active site acetylation, substrate specificity and catalytic activity could be 
affected by the R 1870 substitution (Walraven et al., 2008). 
Previous studies have reported NA T1 *148 to be associated with a reduced N-
acetylation phenotype. For example, in peripheral blood mononuclear cells, NAT1 14B 
was reported to result in reduced N-acetyltransferase activities and protein levels 
(Hughes et aI., 1998). Recombinant NAT1 14B expression in yeast demonstrated 
reduced N- and O-acetylation, protein levels and increased proteasomal degradation 
(Butcher et aI., 2004; Fretland et aI., 2001; Fretland et aI., 2002). NAT114 expressed in 
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mammalian cells also resulted in decreased in reduced V max but increased substrate Km 
towards p-aminobenzoic acid (PABA). 
Modifications in NAT1 protein activity are biologically relevant because formation 
of DNA adducts, tumor growth and drug resistance could be altered by differences in 
enzymatic activity. This study reports findings in constructs that completely mimic NAT1 
mRNA by including the 5'- and 3'-UTRs and ORF of the referent, NAT1*4, and of the 
most common allele associated with reduced acetylation, NA T1 *148. This report 
describes NAT1 14B N- and O-acetylation of the urinary bladder carcinogen 4-
aminobiphenyl (ABP). Initial pilot experiments were conducted following recombinant 
expression in yeast (Schizosaccaromyces pombe) followed by more detailed studies 
utilizing recombinant expression in Chinese hamster ovary (CHO) cells. ABP is a 
confirmed bladder carcinogen (Feng et aI., 2002) and strict federal regulations have 
banned industrial uses of ABP (IARC, 1987). However, ABP can still be found as a 
contaminant in color additives, paints, food colors, leather, textile dyes, diesel-exhaust 
particles, cooking oil fumes and commercial hair dyes (Nauwelaers et aI., 2011). 
Mainstream cigarette smoke has been reported to contain up to 23 ng per cigarette and 




Experiments in Yeast 
In situ N-acetylation following recombinant expression of human NAT1 in yeast 
The ORFs of NA T1 *148 and NA T1 *4 were recombinantly expressed in the 
pESP-3 yeast (Schizosaccaromyces pombe) expression system (Stratagene, La Jolla, 
CA). They were cultured in YES media (Teknova, Hollister, CA, 0.5% yeast extract, 
3.0% glucose, 0.0225% adenine, 0.0225% histidine, 0.0225% leucine, 0.0225% uracil, 
and 0.0225% lysine) and grown to an optical density (00) of OAO. Aliquots (10 mL) 
from both the NA T1 *4 and NA T1 *148 expressing cultures were each treated with ASP to 
make total volume concentrations of 10,50 and 100 I-IM ASP. Samples (100 1-11) were 
collected following 30 minute incubation with ASP. 
Acetyl-ASP was separated and quantitated by HPLC as described previously (Hein et 
aI., 2006). 
Experiments in CHO cells 
Polyadenylation site removal 
The bovine growth hormone (SGH) polyadenylation site from the pcDNA5/FRT 
(Invitrogen, Carlsbad, CA) vector was removed to allow the endogenous NAT1 
polyadenylation sites to be active. This was accomplished by digestion of pcDNA5/FRT 
at 37°C with restriction endonucleases, Apal and Sphl (New England Siolabs, Ipswich, 
MA), followed by overhang digestion with T4 DNA polymerase (New England Siolabs) 
and ligation with T4 Ligase (New England Siolabs). 
Preparation of NA Tb/ NA T1 *4 construct 
NATb/NA T1 *4 construct was created utilizing gene splicing via overlap extension 
(Horton et aI., 1989) by amplifying the 5'-UTR and the coding region/3'-UTR separately 
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and then fusing the two regions together. Beginning with a frequently used transcription 
start site of the NATb promoter, the 5'-UTR (Barker et aI., 2006; Husain et aI., 2004) was 
amplified from cDNA prepared from RNA isolated from homozygous NAT1*4 HepG2 
cells. All primer sequences used are shown in Table 1. The primers used to amplify the 
NATb 5'-UTR region were Lkm40P1 and NAT1 (3') ORF Rev. The coding region and 3'-
UTR were amplified as one piece from NA T1 *4 human genomic DNA with 
NA T1 *4INA T1 *4 genotype. The forward primer used to amplify the coding region/3' -UTR 
was NAT1 (3') ORF Forward while the reverse primer was pcDNA5distai Reverse. The 
two sections, the 5'-UTR and the coding region/3'UTR, were fused together via overlap 
extention and amplification of the entire product using nested primers. The forward 
nested primer was P1 Fwd Inr Nhel and the reverse nested primer was NAT1 Kpn Rev. 
The forward nested primer included the Kpnl endonuclease restriction site and the 
reverse nested primer contained the Nhel endonuclease restriction site to facilitate 
cloning. The pcDNA5/FRT vector and NATbINAT1*4 allelic segments were digested at 
37°C with restriction endonucleases Kpnl and Nhel (New England Biolabs). The 
NATblNA T1 *4 construct was then ligated into pcDNA5/FRT using T 4 ligase (New 
England Biolabs). 
Preparation of NATblNA T1 *148 
To construct the NATblNA T1*148 pcDNA5/FRT plasmid, the NATbINAT1*4 
pcDNA5/FRT and a previously constucted NA T1 *148 allelic contruct expressed in a 
yeast vector, pESP-3 (Stratagene, La Jolla, CA) (Fretland et aI., 2001), were both 
incubated at 37° with restriction enzymes, Sbfl and Aflll (NEB). Following restriction 
digestion, the NATblNA T1 *4 pcDNA5/FRT and the 476 bp segment of NA T1 *148 
(including G560A) were gel purified and ligated utilizing T 4 ligase (New England 
Biolabs). All constructs were sequenced to ensure integrity of allelic segments and 
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junction sites. These constructs that contain NATb 5'-UTR, coding region of NA T1 *4 or 
NAT1*14B, and 3'-UTR are illustrated in Figure 3-1 and referred to as NAT1*4 and 
NA T1 *14B throughout this manuscript. 
Cell culture 
UV5-CHO cells, a nuclease excision repair (NER)-deficient derivative of M8 which 
are hypersensitive to bulky DNA lesions, were obtained from the ATCC (catalog number: 
CRL-1865). Unless otherwise noted, cells were incubated at 37°C in 5% CO2 in 
complete alpha-modified minimal essential medium (a-MEM, Lonza, Walkersville, MD) 
without L-glutamine, ribosides, and deoxyribosides supplemented with 10% fetal bovine 
serum (Hyclone, Logan, UT), 100 units/mL penicillin (Lonza), 100 jJg/mL streptomycin 
(Lonza), and 2 mM L-glutamine (Lonza). The UV5/CHO cells used in this study were 
previously stably transfected with a single Flp Recombination Target (FRT) integration 
site (Metry et aI., 2007). The FRT site allowed stable transfections to utilize·the Flp-In 
System (Invitrogen). When co-transfected with pOG44 (Invitrogen), a Flp recombinase 
expression plasmid, a site-specific, conserved recombination event of pcDNA5/FRT 
(containing either NATalNAT1 *4 or NATbINAT1*4) occurs at the FRT site. The FRT site 
allows recombination to occur immediately downstream of the hygromycin resistance 
gene, allowing for hygromycin selectivity only after Flp-recombinase mediated 
integration. The UV5/FRT cells were further modified by stable integration of human 
CYP1A1 and NADPH-cytochrome P450 reductase gene (POR) (Metry et aI., 2007). 
They are referred to in this manuscript as UV511 A 1 cells. 
48 
Stable transfections 
Stable transfections were carried out using the Flp-In System (Invitrogen) into 
UV511A1 cells that were previously stably transfected with a FRT site (as noted above). 
The pcDNA5/FRT plasm ids containing human NATblNA T1 *4 or NATblNA T1 *148 were 
co-transfected with pOG44 (Invitrogen), a Flp recombinase expression plasmid. 
UV511A 1 cells were stably transfected with pcDNA5/FRT containing NATbINAT1*4 and 
NATblNA T1 *148 constructs using Effectene transfection reagent (Qiagen, Valencia, 
CA) following the manufacturer's recommendations. Since the pcDNA5/FRT vector 
contains a hygromycin resistance cassette, cells were passaged in complete a-MEM 
containing 600 IJg/mL hygromycin (Invitrogen) to select for cells containing the 
pcDNA5/FRT plasmid. Hygromycin resistant colonies were selected approximately 10 
days after transfection and isolated with cloning cylinders. 
Determination of in vitro (in-solution biochemistry) kinetic parameters of N-acetylation for 
NAT1 4 and NAT1 14B 
Lysate was prepared by centrifuging the cells and resuspending pellet in 
homogenization buffer (20 mM NaP04 pH 7.4, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 
2 IJg/mL aprotinin and 2 mM pepstatin A). The resuspended cell pellet was subjected to 
3 rounds of freezing at -80°C and thawing at 37°C and then centrifuged at 15,000xg for 
10 min. In vitro assays using PABA or ABP were conducted and acetylated products 
were separated utilizing HPLC as previously described (Hein et aI., 2006). Preliminary 
studies optimized reactions with respect to linearity of time and protein concentration. 
PABA and ABP kinetic constants were determined at a fixed concentration of 100 IJM 
acetyl coenzyme A (AcCoA). PABA kinetic constants were determined using varying 
PABA concentrations between 11.7 - 3000 IJM. ABP kinetic constants were determined 
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using varying ABP concentrations between 11.7 - 3000 jJM. Reactions containing 
substrate, AcCoA and enzyme were incubated at 3TC for 10 min. Reactions were 
terminated by the addition of 1/10 volume of 1 M acetic acid and centrifuged at 15,OOOXg 
for 10 min. Measurements were adjusted according to baseline measurements using 
Iysates of the UV5/CYP1A 1 cell line and normalized by the amount of total protein. 
Protein concentrations were measured using the method of Bradford (Bio-Rad, 
Hercules, CA). Vmax, Km, and Kcat were determined by fitting substrate concentration and 
velocity data to the hyperbolic Michaelis-Menten model. All calculations were 
determined using GraphPad Prism Software (Graphpad Software, La Jolla, California). 
Determination of in situ (whole-cell assay) kinetic parameters of NAT1 4 and NAT1 14B 
In situ kinetic parameters were determined by in a whole cell assay using media 
spiked with varying concentrations of PABA or ABP. PABA kinetic constants were 
determined using varying PABA concentrations between 2.25 - 300 jJM. ABP kinetic 
constants were determined using varying ABP concentrations between 0.19 and 25 jJM. 
The cells were incubated at 37°C and media was collected after 1 h (PABA) or 22 min 
(ABP), 1/10 volume of 1M acetic acid was added, and the mixture was centrifuged at 
13,OOOxg for 10 min. Values were normalized to the amount of cells present at time of 
media removal. The supernatant was injected into the reverse phase HPLC column and 
N-acetyl-PABA was separated and quantitated as described above. Vmax and Km were 
determined as described above. 
Determination of in vitro kinetic parameters of O-acetylation for NAT1 4 and NAT1 14B 
N-hydroxy-4-aminobiphenyl (N-OH-ABP) O-acetyltransferase assays were 
conducted and product was separated from substrate using HPLC as previously 
described (Metry et aI., 2007). Assays containing 50 jJg total protein, N-OH-ABP, 
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AcCoA, and 1 mg/mL deoxyguanosine (dG) were incubated at 37°C for 10 min. N-OH-
ABP kinetic constants were determined at a fixed concentration of 100 IJM AcCoA and 
N-OH-ABP concentrations between 0.78 and 200 IJM. Reactions were stopped with the 
addition of 100 IJL of water saturated ethyl acetate and centrifuged at 13,000xg for 10 
min. The organic phase was removed, evaporated to dryness, redissolved in 100 IJL of 
10% ACN and injected onto the HPLC. Vmax, Km, and !<cat were determined as described 
above. 
Measurement of NAT1 Protein 
The amount of NAT1 produced in UV511A1 cells stably transfected with NAT1*4 or 
NA T1 *14B was determined by western blot. Cell Iysates were isolated as described 
above. Varying amounts of lysate were mixed 1: 1 with 5% l3-mercaptoethanol in 
Laemmli buffer (Bio-Rad), boiled for 5 min, and resolved by 12% SDS-PAGE. The 
proteins were then transferred by semi-dry electroblotting to polyvinylidene fluoride 
(PVDF) membranes. The membranes were probed with G5, a monoclonal mouse anti-
NAT1 (1 :200) Santa Cruz Biotechnology, Santa Cruz, CA) and with horseradish 
peroxidase (HRP)-conjugated secondary donkey anti-mouse IgG antibody (1 :2,000) 
(Santa Cruz). Supersignal West Pico Chemiluminescent Substrate was used for 
detection (Pierce). To determine a quantitative amount of NAT1 protein in lysate 
collected from cells stably transfected with NAT1*4 or NAT1*14B, a standard curve was 
obtained from loading 0.14 IJg - 1.09 ng of purified NAT1 (Abnova, Taipei, Taiwan). 
Intensities of varying amounts of lysate (55, 28, and 14 IJg) from NAT1 4 and NAT1 14B 
were compared to intensities of the standard curve to determine the amount of NAT1 
protein in the lysate. Kinetic properties of the NA T1 antibody binding of the purified 
protein and to NAT1 from sample lysate were assumed to be the same. Densitometric 
analysis was performed using Quantity One Software (Bio-Rad). 
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DNA Isolation and dG-C8-ABP Quantitation 
DNA was isolated and dG-C8-ABP adducts were quantitated with modifications to a 
previously described method (Metry et aI., 2007). Stably transfected cells grown to 
approximately 80% confluency in 15 cm dishes were incubated in complete a-MEM 
media containing 1.56, 3.13, 6.25, 12.5 IJM ABP or vehicle alone (0.5% DMSO) at 37°C. 
The cells were collected following 24 h of treatment, centrifuged for 5 min at 260xg, and 
the pellet was resuspended in 2 volumes of homogenization buffer (20 mM sodium 
phosphate pH 7.4, 1 mM EDTA), 0.1 volumes of 10% SDS and 0.1 volume of 20 mg/mL 
Proteinase K and allowed to incubate overnight at 37°C. The DNA was extracted using 
phenol/chloroform:isoamyl alcohol and precipitated with isopropanol. The pellet was 
dried and resuspended in 500 IJL of DNA adduct buffer (5 mM Tris pH 7.4, 1 mM CaCI2, 
1 mM ZnCI2, and 10 mM MgCI2)' The DNA was quantitated by spectrophotometry at 
A260 . Five hundred pg of internal standard (dG-C8-ABP-d5, Toronto Research 
Chemicals, North York, Ontario, Canada) was added to 30 IJg of sample DNA, treated 
with 10 units DNase I (Sigma) for 1 h at 37°C followed by treatment with 10 units 
nuclease P1 (Sigma) for 6 h. The reactions were then treated with 10 units of alkaline 
phosphatase (Sigma) overnight at 37°C. The samples were then loaded onto PepClean 
C-18 Spin Columns (Thermo Fisher Scientific), washed with 10% acetonitrile (ACN), 
eluted with 50% ACN by centrifugation at 2000xg and dried. The samples were 
reconstituted with 25 IJL 5% ACN in 2.5 mM NH4HC03 just before analysis and 10 IJL of 
the sample was analyzed by Accela LC System (Thermo Scientific, San Jose, CA) 
coupled with a L TQ-Orbitrap XL mass spectrometer (Thermo Scientific, San Jose, CA). 
Samples were loaded onto a 30 x 1 mm x 1.9 IJm Hypersil GOLD column (Thermo 
Scientific, San Jose, CA) and eluted with a 12.5 min binary solvent gradient (Solvent A: 
5% ACN/0.1 % formic acid and Solvent B: 95% ACN/0.1 % formic acid) at 50 IJllmin. The 
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gradient started from 5% Solvent B, increased linearly to 75% Solvent B in 10 min, and 
then remained at 75% B for 2.5 min. The eluates were ionized byelectrospray 
isonization and dG-C8-ABP and dG-C8-ABP-d5were detected with linear ion trap and 
detected by multiple reaction monitoring using the transitions of m/z 435.2 to m/z 319.2 
(dG-C8-ABP) and m/z 440.2 to m/z 324.2 (dG-C8-ABP-d5). Concentrations of dG-C8-
ABP were calculated from peak areas of dG-C8-ABP and dG-C8-ABP-d5 with a 
calibration curve from synthetic dG-C8-ABP and dG-C8-ABP-d5. 
Measurement of Cytotoxicity 
Assays for cell cytoxicity were carried as previously described cyJu et aI., 1997) with 
slight modifications. Cells were grown in HAT medium (30 mM hypoxanthine, 0.1 mM 
aminopterin, and 30 mM thymidine) for 12 doublings. Cells (1x106) were plated, allowed 
to grow for 24 h and were then treated with 1.56, 3.13, 6.25 or 12.5 IJM ABP (Sigma) or 
vehicle alone (0.5% DMSO) in media. After 48 h, cells were plated to determine survival 
following exposure to ABP. To determine cloning efficiency following each dose of ABP, 
100 cells were plated in triplicate in 6 well-plates and allowed to grow for 7 days in non-
selective media. Colonies were counted and expressed as percent of vehicle control. 
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RESULTS 
Initial experiments performed in yeast (in situ) resulted in higher NAT1 14B N-
acetylation at 10 IJM (p<0.001) and 50 IJM ABP (p<0.05) compared to NAT1 4. There 
was no difference in N-acetylation between NAT1 14B and NAT1 4 following exposure to 
100 IJM ABP (Figure 3-2). The results of subsequent experiments performed in CHO 
cells are described below. 
Kinetic parameters of the referent, NA T1 4, and the variant, NAT1 14B in vitro 
(per mg total protein in-solution biochemistry) are shown in Table 3-2. The apparent Km 
of NAT1 14B was higher for PABA (p<0.0001) compared to NAT1 4 whereas the 
apparent Km of NAT114B was lower for ABP (p<0.0001) and N-OH-ABP (p<0.0001) 
when compared to NAT1 4. The apparent Vmax of NAT1 14B was lower for PABA 
(p<O.OOO1), ABP (p<.OOO1), and N-OH-ABP (p<0.0001) when compared to NAT1 4. The 
apparent VmaxlKm of NAT1 14B was lower for PABA (p<O.OOO1), higher for N-OH-ABP 
(p<O.OOO1), and not significantly different for ABP (p>0.05) when compared to NAT1 4. 
The kinetic parameters, apparent Km and Kcat also were determined in vitro (per 
mg NAT1 protein in solution biochemistry) for the referent, NAT1 4 and the variant, 
NAT1 14B (Table 3-2). The apparent Kcat of NAT1 14B was lower for PABA (p<0.0001) 
but higher for N-OH-ABP (p<0.0001) when compared to NAT1 4. There was no 
significant difference in apparent Kcat for ABP between NAT1 14B and NAT1 4 (p>0.05). 
The apparent KcatfKm of NAT1 14B was lower for PABA (p<0.0001) but higher for ABP 
(p<0.05) and N-OH-ABP (p<0.0001) when compared to NAT1 4. 
Apparent Km and Vmax for PABA and ABP also were determined in situ (per 
million cells in a whole cell based assay) for the referent, NAT1 4, and the variant, NAT1 
14B (Table 3-3). The apparent Km of NAT1 14B was not significantly different for PABA 
(p>0.05) but was significantly lower for ABP (p<0.0001) when compared to NAT1 4. The 
apparent Vmaxof NAT1 14B was lower for PABA (p<0.05) and ABP (p<0.0001) when 
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compared to NAT1 4. The apparent VmaxfKm of NAT1 14B for PABA was significantly 
less (p<0.05) but was significantly higher for ABP (p<0.05) when compared to NAT1 4. 
Expression of NAT1 14B and NAT1 4 was determined by western blot (Figure 3-
3). Based on intensities determined from the standard curve, after loading 55, 28, or 14 
j.Jg of total protein lysate, there were 154, 77, and 38 ng of NAT1 4 protein and 38, 19, 
and 10 ng of NAT1 14B protein. Overall, NAT1 14B resulted in a 4-fold reduction in 
NAT1 protein compared to NAT1 4 (p<0.001). 
ABP-induced cytotoxicity was also determined in cells stably transfected with 
NA T1 *4 and NA T1 *148 (Figure 3-4a). Significantly more ABP-induced cytotoxicity was 
observed in NA T1 *148 transfected cells following exposures to each ABP concentration. 
ABP-induced dG-C8-ABP adducts in cells stably transfected with NA T1 *4 and 
NA T1 *148 were determined (Figure 3-4b). Significantly more dG-C8-ABP adducts were 
observed following exposures between 1.56 - 12.5 j.JM ABP in cells transfected with 










(a) Schematic of NAT1 genomic structure and most common RNA transcribed by 
the NATb promoter. (b) Constructs including 5'-UTR, open reading frame (exon 9) 





















Figure 3-2: ABP N-acetylation by NAT1 4 and NAT114B expressed in yeast 
In situ ASP N-acetylation assay of yeast cultures recombinantly 
expressingNA T1 *4 and NA T1 *148 per million cells. Error bars represent mean 
of 3 separate collections ± SEM. Difference determined following a Student's t-
test and significance denoted by **p<O.001 and *p<.OS. 
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Primer Name Use Sequence 
Lkm40P1 NATb 5-'UTR forward specific peR 5'-GGCCGCGGCAITCAGTCTAGITCCTGGITGCC-3' 
P1 Fwd Inr Nhel NATb 5'-UTR forward specific nested peR 5'-TIT AAAGCTAGCA ITCAGTCTAGTCTAGITCCTGGITGCCGGCT-3' 
NAT1 (3') ORF Rev NATaiNATb 5'-UTR reverse peR 5'-ITCCTCACTCAGAGTCITGAACTCTAIT-3' 
NAT1 (3') ORF For NAT1 coding region forward peR 5'-AGACATCTCCATCATCTGTGTITACTAGT-3' 
pcDNA5 FRTdistal Rev NAT1 3'-UTR reverse peR 5'-CGTGGGGATACCCCCTAGA-3' 
NAT1 KPN-Rev NAT1 3'-UTR reverse nested peR 5'-ATAGTAGGTACCTCTGAAITATAGATAAGCAAAGAITCAGAITCT-3' 
Table 3-1: Primers used to amplify NATb/NAT1*4 construct 
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Allele Substrate Km{app) Vmax{app) Vmax/Km Kcat{app) KcatlKm 
J.lM nmole min-1 mg-1 mL min-1 mg-1 min-1 min-1 J.lM-1 
NAT1*4 PABA 42.9±3.3 116±3 2.72±0.21 2399±57 56.5±4.3 
430±1 a 18.5±1.5 b 0.043±0.002 b 1552±97 3.61±0.20 
NAT1*14B b b 
NAT1*4 ABP 273±46 57.7±5.8 0.218±0.018 1200±122 4.52±0.38 
65.6±3.9 18.0±4.3 b 0.280±.031 1760±128 22.9±0.23c 
NAT1*14B b 
NAT1*4 N-OH-ABP 141±1.1 2.97±0.19 0.0211 ±0.0014 35.1±68 0.250±0.02 
46.8±1.3 1.76±0.03 b 0.038±0.001 c 147±7 a 3.15±0.23 
NAT1*14B b c 
NAT1*4 AcCoA 6.23±0.75 1.25±0.04 0.204±0.019 25.9±0.7 4.24±0.38 
16.8±2.2 c 1.50±0.29 0.087±0.005 b 126±24c 7.31±0.45 
NAT1*14B a 
Table 3-2: NAT1 4 and NAT1 148 kinetic constants determined in vitro 
NAT1 4 and NAT1 14B kinetic constants determined in vitro (per mg total protein). 
PABA, ABP, and N-OH-ABP constants were determined at a fixed concentration of 100 
IJM AcCoA. AcCoA kinetic constants were determined at a fixed concentration of 100 
IJM N-OH-ABP. Table values represent mean ± SEM for 3-6 individual determinations. 
Differences were tested for significance by Student's t-test. aSignificantly higher than 
NAT1 4 (p<0.0001); bsignificantly lower than NAT1 4 (p<0.0001); Csignificantly higher 
than NAT1 4 (p<0.05). 
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Allele Substrate Km(app) Vmax(app) Vmax/Km 
nmole min-1 million nmole min-' 
IJM cells-1 million cells-
1 
~M-1 
NAT1*4 PABA 9S.S±1.1 0.16±0.01 1.71±0.08 
NAT1*14B 
72.1±11.1 0.101±0.018a 1.1±0.09a 
NA T1 *4 ABP 10.S±0.6 0.024±.0007 2.4±0.1 
NAT1*14B 
2.3±0.2b 0.0063±0.000Sb 2.9±0.1c 
Table 3-3: NAT1 4 and NAT1 148 kinetic constants determined in situ 
NAT1 4 and NAT1 14B kinetic constants determined in situ (per million cells). Table 
values represent mean ± SEM for 3-6 individual determinations. Differences were tested 
for significance by Student's t-test. asignificantly lower than NAT1 4 (p<O.OS); 
bsignificantly lower than NAT1 4 (p<0.0001); Csignificantly higher than NAT1 4 (p<O.OS). 
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Figure 3-3: NAT1 4 and NAT1 148 protein expression 
Western blot to determine relative protein expression of NAT1 4 and NAT1 14B. (a) 
representative western blot and (b) densitometric analysis. Loading either 28 or 14 I-Ig of 
total protein from lysate, NAT1 14B resulted in approximately 4-fold less NA T1 protein 
than NAT1 4. In 28 I-Ig of total protein from lysate, 77 I-Ig of NAT1 4 and 18 I-Ig of NAT1 
14B protein were detected (p<O.001). One clone stably expressing NA T1 *4 and two 
clones stably expressing NA T1 *148 were evaluated. Bars represent mean ± SEM for 3 
western blots and significance was determined by Student's t-test. 
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Figure 3-4: ABP-induced cytotoxicity and DNA adducts 
ABP-induced cytotoxicity (a) and dG-C8-ABP adducts (b) in cells stably transfected with 
NA T1 *4 and NA T1 *148. Significantly more cytotoxicity was observed for NAT1 14B than 
NAT1 4 following all ABP exposures between 1.56 - 12.5 IJM. Significantly more adducts 
were observed following all exposures examined in cells expressing NAT1 14B than in 
cells expressing NAT1 4. Values were adjusted for baseline values of UV511A1 cells. 
Bars represent mean ± SEM for 3 determinations and significance was determined by 
Student's t-test. ("*) p<O.05, ("**) p<O.001, and (***) p<O.0001. 
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DISCUSSION 
Smokers possessing NA T1 *148 have been associated with increased risk for 
lung cancer compared to individuals possessing NA T1 *4 (Bouchardy et aI., 1998). 
Previous studies have reported that NA T1 *148 is associated with reduced N- and 0-
acetylation of various substrates including PABA, p-aminosalisylic acid, and various 
arylamine carcinogens (Fretland et aI., 2001; Fretland et aI., 2002; Hughes et aI., 1998; 
Zhu and Hein, 2008). Recombinant NAT1 14B expression in yeast demonstrated lower 
N- and O-acetylation, NAT1-specific protein levels and increased NAT1 proteasomal 
degradation (Butcher et aI., 2004; Fretland et aI., 2001; Fretland et aI., 2002). Similarly, 
NAT1 14B expressed in COS-1 cells also resulted in less NAT1 N- and O-acetylation, 
NAT1 protein level, and NAT1 Vmax, but higher PABA Km when compared to the referent, 
NAT1 4 (Zhu and Hein, 2008). Our kinetic constant determinations performed in CHO 
cells confirmed that NAT1 14B results in a lower apparent Vmax (both in vitro and in situ) 
for PABA when compared to the referent, NAT1 4. We also confirmed the higher PABA 
apparent Km in NAT1 14B determined in vitro when compared to NAT1 4. In addition to 
PABA acetylation, we also report on N- and O-acetylation of ABP and N-OH-ABP. ABP 
is a human urinary bladder carcinogen found as a contaminant in cigarette smoke, food 
dyes, paints, textile dyes, engine exhaust, and commercial hair dyes (Nauwelaers et aI., 
2011 ). 
The arylamine substrate Km of NAT1 is dependent on the AcCoA concentration 
because acetylation proceeds via a 'ping-pong bi-bi' reaction (Weber and Hein, 1985). 
Because AcCoA concentrations have been measured in vivo in the low micromolar 
range (Reeves et aI., 1988), we chose an in vitro AcCoA concentration of 100 jJM. In 
order to better mimic NAT1 catalyzed acetylation in vivo, kinetic constants were 
determined in situ (when possible) allowing the concentration of AcCoA to be provided 
by the cell. 
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Studies performed in situ using NAT1 14B and NAT1 4 produced in yeast did not 
result in lowered NAT1 14B N-acetylation of ABP (Figure 4-2) as previous studies had 
shown in vitro (Fretland et aI., 2002). This result was surprising as previous studies 
reported NAT1 14B activity and protein expression to be lower than NAT1 4. To further 
explore the NAT1 14B acetylation status, studies were conducted in stably transfected 
CHO cells. 
When comparing apparent Vmax (in vitro), the NAT1 14B apparent Vmax was lower 
than the NAT1 4 for all substrates studied. The apparent Vmax describes the maximum 
enzyme velocity extrapolated to maximum substrate concentrations. The lower apparent 
Vmax for PABA, ABP, and N-OH-ABP indicate that at high substrate concentrations, 
NAT1 14B has a decreased ability to metabolize the substrate when compared to NAT1 
4. The apparent VmaxfKm, or intrinsic clearance, describes an enzyme's ability to 
metabolize a substrate at substrate concentrations well below the Km and has also been 
shown to correlate well to human liver clearance (Chen et aI., 2011; Northrop, 1999). 
Although there are limitations in using VmaxfKm as a comparator of two enzymes, we 
determined apparent Vmax for comparison at high substrate concentrations and apparent 
VmaxfKm for comparison at low substrate concentrations (Eisenthal et aI., 2007). For 
PABA, the NAT1 14B apparent VmaxfKm was lower than NAT1 4. In contrast, no 
significant difference was observed between NA T1 14B and NA T1 4 apparent V maxfKm 
towards the N-acetylation of ABP. Surprisingly, the NAT1 14B apparent VmaxfKm for the 
O-acetylation of N-OH-ABP was higher in NA T1 *148 CHO cells compared to NA T1 *4. 
This indicates that the status of NAT1 14B intrinsic clearance compared to NAT1 4 
intrinsic clearance is substrate dependent. 
Transfection of NA T1 *148 resulted in approximately a 4-fold less NA T1 protein 
expression compared to NA T1 *4. When the amount of NAT1 protein was used to 
calculate apparent Kcat (determined in vitro), the results suggested that the lower NAT1 
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14B apparent Vmax for these substrates is due to a reduction in NAT1 protein, not a 
reduction in the acetylation rate of the NAT1 14B enzyme. For example, although the 
NAT1 14B apparent Vmax for N-OH-ABP was lower than the NAT1 4, the NAT114B 
apparent !<cat for N-OH-ABP was higher than NAT1 4. This difference in Vmaxcompared 
to Kcat indicates that the lowered NAT1 14B apparent Vmax is caused by a reduction in 
protein expression. Butcher et. al (2004) reported that NAT1 14B and other NAT1 
genetic variants associated with reduced enzymatic activity have reduced ability to be 
acetylated which resulted in an unstable NAT1 protein. Therefore, NAT1 14B was 
reported to be less stable and have increased proteasomal degradation compared to 
NAT1 4 (Butcher et aI., 2004). Our study confirmed that NAT1 14B resulted in reduction 
of NAT1 protein. 
Because determination of kinetic parameters is dependent upon AcCoA 
concentration, acetylation was measured in situ to allow the concentration of AcCoA to 
be provided by the cell. When comparing Vmax (in situ), the NAT1 14B apparent Vmax was 
lower than the NAT1 14B for all substrates studied. When evaluated in situ, PABA NAT1 
14B apparent VmaxfKm or intrinsic clearance was lower when compared to NAT1 4 In 
contrast, for ABP, the in situ NAT1 14B apparent VmaxlKm was higher when compared to 
NAT1 4. Because kinetic parameters of N-OH-ABP could not be determined in situ, an 
in vitro determination was performed. Like ABP, the NAT1 14B apparent VmaxlKm for N-
OH-ABP was higher compared to NA T1 4. These findings indicate that differences in 
apparent VmaxfKm between NAT1 14B and NAT1 4 are substrate dependent. Risk for 
individuals possessing NAT1*14B is also likely exposure dependent. Increased 
apparent VmaxlKm indicates that NAT1 14B has an increased ability to metabolize ABP 
and N-OH-ABP at low substrate concentrations compared to NAT1 4 (Northrop, 1999). 
Since low substrate concentrations are relevant in vivo, the higher NA T1 14B apparent 
VmaxlKm suggests that differences between NAT1 14B and NAT1 4 catalyzed ABP 
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acetylation should be observed in vivo. Therefore, risk for individuals possessing 
NA T1 *14B is dependent on exposure type and can also be altered depending on 
exposure level. 
NAT1 homology modeling predicted that the R1870 could affect NAT1 active site 
acetylation and enzymatic activity (Walraven et aI., 2008). Because changes in binding 
of AcCoA and substrate specificity are likely altered due to the R 1870, it is not surprising 
that differences in intrinsic clearance between NAT1 14B and NAT1 4 were observed. 
We confirmed that R 1870 modifies substrate affinity, albeit in opposite directions 
depending on substrate. Further epidemiological studies are necessary to determine 
which carcinogen exposures result in increased risk for individuals possessing 
NA T1 *14B. Exposure dependent risk has been previously reported for an N-
acetyltransferase 2 (NAT2) (Hickman et aI., 1995; Zang et aI., 2007). The NA T2*7B 
allozyme exhibits altered kinetic parameters of substrates including sulfamethazine and 
dapsone but not for other substrates such as 2-aminofluorene and isoniazid when 
compared to the referent, NAT2*4 (Hickman et aI., 1995; Zang et aI., 2007). Our study 
is the first report of exposure dependent behavior for a variant of NAT1. 
In addition to higher apparent VmaxfKm for NAT1 14B towards ABP and N-OH-
ABP when compared to NAT1 4, ABP-induced DNA-adducts and cytoxicity were higher 
for NAT1 14B compared to NAT1 4. Measurement of DNA adduct levels following 
exposure to ABP is a biological endpoint very relevant to cancer risk. Because NAT1 
14B resulted in increased ABP-induced DNA adducts, our results suggest that 
individuals possessing the NA T1 *14B allele likely have increased risk compared to those 
who are homozygous for NA T1 *4 following low (environmental) dose exposure to ABP. 
NAT1 14B is not simply associated with "slow acetylation" but rather is substrate 
dependent, since NAT1 14B exhibits lower N-acetylation catalytic efficiency of PABA but 
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higher N- and O-acetylation catalytic efficiency as well as DNA adducts following 
exposure to the human carcinogen ABP. 
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CHAPTER 4 
FUNCTIONAL ANALYSIS OF NAT1*10VS NAT1*4IN COMPLETE NATbAND 
NATa mRNA CONSTRUCTS 
INTRODUCTION 
Human arylamine N-acetyltransferase 1 (NAT1) is a phase II cytosolic isozyme 
responsible for the biotransformation of many arylamine compounds including 
pharmaceuticals and environmental carcinogens (Hein et aI., 2000). NAT1 has been 
implicated in several types of cancer due to its role in metabolic activation of arylamine 
carcinogens, and recent findings report NAT1 may be important for cell growth and 
survival of cancer cells (Tiang et aI., 2011) NAT1 has been found in nearly all tissues 
studied including fetal tissue (Boukouvala and Sim, 2005; Grant et aI., 1989; Pacifici et 
aI., 1986). NAT1 is capable of both N-acetylation and O-acetylation. Following N-
acetylation (inactivation) the innocuous acetylated compounds can be excreted from the 
body. However, following O-acetylation (activation) the compound forms an unstable N-
acetoxyarylamine which undergoes heterolytic cleavage to yield a highly reactive 
nitrenium ion. These nitrenium ions are highly electrophilic and can react with proteins 
or DNA to form adducts. Therefore, following exposure to arylamine carcinogens, the 
acetylator phenotype may modulate individual susceptibility to cancer. 
NAT1 and NAT2 are known to be highly polymorphic with over 20 alleles 
identified for each. Polymorphic variations of NAT1 and NAT2 can result in altered 
acetylation capacity. The functional effects of NAT2 polymorphisms have been well 
characterized in relationship to their phenotype, but the functional effects of NAT1 
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polymorphisms remain poorly understood. The most common NAT1 polymorphisms are 
located in the region 3' to the open reading frame; however conflicting results about their 
effect on acetylation capacity have been reported. NA T1 *1 0 is the most common NAT1 
variant allele in many populations and is characterized by two SNPs in the 3'-UTR, 
T1088A (rs1057126) and C1095A (rs15561). One study suggested that NAT1*10 has 
higher acetylation capacity than the referent allele, NA T1 *4, (Bell et aL, 1995a), while 
another have reported no difference (de Leon et aL, 2000). There are no amino acid 
changes due to these polymorph isms, but the T1088A causes a change in the second 
consensus polyadenylation signal (AAIAAA - AA8.AAA). It has been speculated that 
this change in polyadenylation signal may give rise to a difference in mRNA stability and 
modulated acetylation activity of NAT1 10 (Bell et aL, 1995a). The 3'-UTR of a gene 
contains binding sites for important translational regulatory elements that include 
microRNAs, proteins or protein complexes, cytoplasmic polyadenylation elements (CPE) 
and polyadenylation signals (AAUAAA) (Mishra et aL, 2008). It has been shown that 
SNPs in 3'-UTRs of dihydrofolate reductase (DHFR), thrombin and resistin genes cause 
functional affects and alter disease risk (Gehring et aL, 2001; Mishra et aL, 2008; Pizzuti 
et aL, 2002). 
In addition to the high allelic frequency in many populations, NA T1*10 is also of 
great interest because it has been associated with increased risk of so many different 
forms of cancer. NA T1 *10 heterozygous genotype is associated with increased odds 
ratios for non-Hodgkin lymphoma (Morton et aL, 2006), gastric adenocarcinoma (Boissy 
et aL, 2000), prostate cancer (Hein et aL, 2002) and breast cancer (Stephenson et aL, 
2010) when compared to the homozygous NA T1 *4 genotype. It has also been reported 
that cancer risk associated with NA T1 *10 is further modulated by exposure to 
environmental carcinogens found in cigarette smoke, meats cooked at high 
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temperatures, and the use of hair dye. For example, frequent consumption of red meat 
in combination with NA T1 *10 is associated with an increased odds ratio for colorectal 
cancer (Lilla et aI., 2006) and the use of dark, permanent hair dye in combination with 
NA T1*10 is associated with an increased risk for non-Hodgkin lymphoma (Morton et aI., 
2007). Heavy smokers possessing the NA T1*10 allele have an increased risk for 
developing pancreatic cancer compared to non-smokers (Li et aI., 2006) and for 
developing breast cancer (Zheng et al., 1999). The contribution of NA T1 *10 to 
increased cancer risk is not well understood. It is imperative that the phenotype of 
NA T1 *10 be clearly defined in order to resolve the association of NA T1 *10 genotype 
with increased cancer risk. 
The NAT1 gene is located on the small arm of chromosome 8 (Blum et aI., 1990) 
and spans 53 kb. NAT1 is encoded by a single intronless coding exon containing an 
open reading frame (ORF) of 870 base pairs (bp). Several NAT1 transcripts have been 
identified containing various combinations of the 9 noncoding 5'-untranslated region 
(UTR) exons and are known to originate from two distinct promoters, NATa and NATb. 
NATa originates 51.5 kb upstream of the single NAT1 ORF while NATb originates 11.8 
kb upstream of the NAT1 ORF (Barker et aI., 2006; Boukouvala and Sim, 2005; Husain 
et aI., 2004). The reason for the two promoters and the resulting distinct transcripts 
remains unclear. However, there is tissue specific expression between transcripts 
derived from the two major promoters. NA Tb transcripts are expressed in all tissues 
studied, while NATa transcripts are located in kidney, liver, lung and trachea (Barker et 
aI., 2006). Because the NATa transcripts are found only in areas of high environmental 
exposure, differences in transcriptional regulation may necessitate two separate 
promoters. 
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Differences in transcripts derived from the NATb and NATa promoters have been 
reported both in translation and transcription (Butcher et aI., 2005; Millner, 2011). 
Transcripts derived from the NATb promoter are translated more efficiently than 
transcripts derived from the NATa promoter (Butcher et aI., 2005). Chinese hamster 
ovary cells stably transfected with Cytochrome p450 1A1 and NATb/NAT1*4 (mRNA 
type/allele) resulted in lower NAT1 protein, mRNA as wells as N- and 0- acetylation 
compared to cells transfected with NATa/NA T1 *4 (Millner, 2011). Following treatment 
with 4-aminobiphenyl, NATb/NA T1 *4 transfected cells also resulted in higher DNA 
adducts, cytotoxicity and mutants compared to NATa/NAT1 *4 transfected cells (Millner, 
2011 ). 
In addition to polymorphic variation, it may be necessary to consider 
transcriptional and translational regulation to further understand the variation associated 
with NA T1 *10 acetylation activity and effect on cancer risk. I n contrast to previous 
studies which included only the NA T1 open reading frame (ORF), this study employs 
constructs that mimic the most common transcripts originating from the NATb and the 
NATa promoters. In this study, the constructs are referred to as NATb/NA T1 *X or 
NATa/NAT1*X. NATb or NATa refers to the 5' non-coding exons (NCEs) while NAT1*X 
refers to the specific allele. The constructs contain the ORF, the 3'-UTR and all 5' NCEs 
found in the most common NAT1 transcripts originating at the NATb and NATa promoter 
(Figure 4-1) (Barker et aI., 2006; Husain et aI., 2004; Husain et aI., 2007). The 
NATb/NAT1*X construct contains exons 4 and 8 (5' NCEs) and exon 9 (ORF) which has 
been termed transcript Type IIA by Butcher et aI., 2005. The NATa/NA T1*X construct 
contains exons 1, 2, 3, 8 (5' NCEs) and 9 (ORF) which has been termed transcript Type 
1A by Butcher et aI., 2005. In addition to the 5' NCEs and the ORF, the NATb/NA T1*X 
and NATa/NA T1*X constructs also contain 888 nucleotides of the 3'-UTR. The 
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NATblNA T1*X and NATaINAT1*X constructs were employed to provide a more 
comprehensive model of in vivo metabolism and to study any allele specific interactions 
between the 5' -UTR and NA T1 *10 polymorph isms. These constructs were utilized to 
determine N- and 0- acetylation, mRNA levels, protein levels, and polyadenylation 
patterns between cells transfected with NATbINAT1*4 and NATaINAT1*4 as well as 
variants of NA T1 *10 in both mRNA constructs. 
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METHODS 
Polyadenylation site removal 
The bovine growth hormone (BGH) polyadenylation site from the pcDNAS/FRT 
(Invitrogen, Carlsbad, CA) vector was removed to allow the endogenous NA T1 
polyadenylation sites to be active. This was accomplished by digestion of pcDNAS/FRT 
at 37°C with restriction endonucleases, Apal and Sphl (New England Biolabs, Ipswich, 
MA), followed by overhang digestion with T4 DNA polymerase (New England Biolabs) 
and ligation with T4 Ligase (New England Biolabs). 
NATb/NAT1*4, NATb/NAT1*10 NATb/NAT1*10B, NATaINAT1*4, NATaINAT1*10, 
and NATal NA T1 *1 OB construct 
The constructs were created utilizing gene splicing via overlap extension (Horton et 
aI., 1989) by amplifying the S'-UTR and the coding region/3'-UTR separately and then 
fusing the two regions together. Beginning with frequently used transcription start sites 
(Barker et aI., 2006; Husain et aI., 2004), the S'-UTRs were amplified from cDNA 
prepared from RNA isolated from homozygous NA T1 *4 HepG2 cells. All primer 
sequences used are shown in Table 1. The primers used to amplify the NATb S'-UTR 
region were Lkm40P1 and NAT1 (3') ORF Rev while the primers used to amplify the 
NATa S'-UTR region were Lkm41P1 and NAT1 (3') ORF Rev. The coding region and 3'-
UTR were amplified as one piece from homozygous NA T1 *4 or homozygous NA T1 *10 
human genomic DNA. The forward primer used to amplify the coding region/3'-UTR was 
NAT1 (3') ORF Forward while the reverse primer was pcDNASdistal Reverse. The two 
sections, the S'-UTR and the coding region/3'UTR, were fused together via overlap and 
amplification of the entire product using nested primers. The forward nested primer for 
NATb was P1 Fwd Inr Nhel while the forward nested primer for NATa was P3 Fwd Inr 
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Nhel. The reverse nested primer for both NATa and NATb constructs was NAT1 Kpn 
Rev (NAT1*4 and NAT1*10) or NAT1 Kpn Rev 10B (NA T1*10B). Both forward nested 
primers included the Nhe1 endonuclease restriction site and both reverse nested 
primers contained the Kpn1 endonuclease restriction site to facilitate cloning. The 
pcDNA5/FRT vector and NATalNAT1*4 and NATb/NAT1*4 allelic segments were 
digested at 37°C with restriction endonucleases Kpnl and Nhel (New England Biolabs). 
The NA T1 constructs were then ligated into pcDNA5/FRT using T41igase (Invitrogen). 
All constructs were sequenced to ensure integrity of allelic segments and junction sites. 
NATb/NA T1 *10 Construction 
NATb/NAT1*10 constructs were created using the same NATb 5'-UTRs amplified 
from cDNA prepared from NA T1 *4 homozygous RNA isolated from HepG2 cells, while 
the ORF (open reading frame) and region 3' to the ORF were amplified as one piece 
from NA T1 *1 OINA T1 *10 homozygous human genomic DNA. These two sections, the 5' 
UTR and the ORF/region 3' to the ORF were fused together using nested primers. Upon 
sequencing to ensure allelic and junction site integrity, it was discovered that one of the 
NA T1 *10 clones had 4 additional polymorphisms located in the region 3' to the ORF 
including 1571T>C, 1642A>C, 1647 !lCT, and 1716C>T (Table 1). The presence of 
these polymorph isms in NA T1 was verified against NCBI databases. This study refers to 
this allele as NATb/NAT1*10B and was used to compare N-acetylation activity along 
with NATb/NAT1*10 and NATb/NAT1*4. 
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Cell culture 
UV5-CHO cells, a nuclease excision repair (NER)-deficient derivative of M8 which 
are hypersensitive to bulky DNA lesions, were obtained from the ATCC (catalog number: 
CRL-1865). Unless otherwise noted, cells were incubated at 37°C in 5% CO2 in 
complete alpha-modified minimal essential medium (a-MEM, Lonza, Walkersville, MD) 
without L-glutamine, ribosides, and deoxyribosides supplemented with 10% fetal bovine 
serum (Hyclone, Logan, UT), 100 units/mL penicillin (Lonza), 100 IJg/mL streptomycin 
(Lonza), and 2 mM L-glutamine (Lonza). The UV5/CHO cells used in this study were 
previously stably transfected with a single Flp Recombination Target (FRT) integration 
site (Metry et aI., 2007). The FRT site allowed stable transfections to utilize the Flp-In 
System (Invitrogen). When co-transfected with pOG44 (Invitrogen), a Flp recombinase 
expression plasmid, a site-specific, conserved recombination event of pcDNA5/FRT 
(containing either NATaINAT1*4 or NATb/NAT1*4) occurs at the FRT site. The FRT site 
allows recombination to occur immediately downstream of the hygromycin resistance 
gene, allowing for hygromycin selectivity only after Flp-recombinase mediated 
integration. The UV5/FRT cells were further modified by stable integration of human 
CYP1A1 and NADPH-cytochrome P450 reductase gene (POR) (Metry et aI., 2007). 
They are referred to in this manuscript as UV511 A 1 cells. 
Transient Transfection 
UV511A 1 cells were transiently transfected with pcDNA5/FRT (Invitrogen) or 
pEF1N5-His (Invitrogen) containing NATb/NA T1*4, NATb/NA T1*10, and 
NATb/NAT1*10B constructs using Lipofectamine reagent (Invitrogen) following the 
manufacturer's recommendations. UV5/1A1 cells were co-transfected with pCMV-
SPORT-l3gal (l3-galactosidase transfection control plasmid, Invitrogen). The cells were 
harvested the next day. Lysate was prepared by centrifuging the cells and resuspending 
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pellet in lysis buffer (0.2% triton-X 100, 20 mM NaP04 pH 7.4, 1 mM EDTA, 1 mM DTT, 
0.1 mM PMSF, 2 IJg/mL aprotinin and 2 mM pepstatin A). The resuspended cell pellet 
was centrifuged at 13,000xg for 10 min. The supernatant was used to measure N-
acetyltransferase activity and l3-galactosidase activity. 
Stable transfections 
Stable transfections were carried out using the Flp-In System (Invitrogen) into 
UV511A1 cells that were previously stably transfected with a FRT site (as noted above). 
The pcDNA5/FRT plasm ids containing human NATbINAT1*Xand NATaINAT1*Xwere 
co-transfected with pOG44 (Invitrogen), a Flp recombinase expression plasmid. 
UV511 A 1 cells were stably transfected with pcDNA5/FRT containing NATbl NA T1 *4 and 
NATblNA T1 *148 constructs using Effectene transfection reagent (Qiagen, Valencia, 
CA) following the manufacturer's recommendations. Since the pcDNA5/FRT vector 
contains a hygromycin resistance cassette, cells were passaged in complete a-MEM 
containing 600 IJg/mL hygromycin (Invitrogen) to select for cells containing the 
pcDNA5/FRT plasmid. Hygromycin resistant colonies were selected approximately 10 
days after transfection and isolated with cloning cylinders. 
Determination of in vitro N-acetylation for NAT1 4, NAT1 10, and NAT1 10B 
Lysate was prepared as described above. In vitro assays using the NAT1 specific 
substrate para-aminobenzoic acid (PABA, 300 IJM) or 4-aminobiphenyl (ABP, 100 IJM) 
were conducted and acetylated products were separated utilizing HPLC as previously 
described (Hein et aI., 2006). N-acetylation activity was determined at a fixed 
concentration of 1 mM acetyl coenzyme A (AcCoA). Reactions containing substrate, 
AcCoA and enzyme were incubated at 3TC for 10 min. Reactions were terminated by 
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the addition of 1/10 volume of 1 M acetic acid and centrifuged at 15,000Xg for 10 min. 
Measurements were adjusted according to baseline measurements using Iysates of the 
UV5/CYP1 A 1 cell line and normalized by the amount of total protein. Protein 
concentrations were measured using the method of Bradford (Bio-Rad, Hercules, CA). 
All calculations were determined using GraphPad Prism Software (Graphpad Software, 
La Jolla, California). 
In situ N-acetylation by NAT1 4, NAT1 10, and NAT1 10B 
In situ N-acetylation activities were determined by a whole cell assay using 
media spiked with varying concentrations of PABA or ABP. N-acetylation activities were 
determined using varying concentrations of PABA and ABP between 10 and 300 IJM. 
The cells were incubated at 37°C and media was collected after 1 h (PABA) or 22 min 
(ABP), 1/10 volume of 1M acetic acid was added, and the mixture was centrifuged at 
13,000xg for 10 min. Values were normalized to the amount of cells present at time of 
media removal. The supernatant was injected into the reverse phase HPLC column and 
N-acetyl-PABA or N-acetyl-ABP was separated and quantitated as described above. 
Determination of in vitro O-acetylation for NAT1 4 and NAT1 10 and NAT1 10B 
N-hydroxy-4-aminobiphenyl (N-OH-ABP) O-acetyltransferase assays were 
conducted and product was separated from substrate using HPLC as previously 
described (Metry et aI., 2007). Assays containing 50 IJg total protein, N-OH-ABP (100 
IJM), AcCoA (1 mM), and 1 mg/mL deoxyguanosine (dG) were incubated at 37°C for 10 
min. Reactions were stopped with the addition of 100 IJL of water saturated ethyl acetate 
and centrifuged at 13,000xg for 10 min. The organic phase was removed, evaporated to 
dryness, redissolved in 100 IJL of 10% ACN and injected onto the HPLC. 
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Measurement of NAT1 Protein 
The amount of NA T1 produced in UV511 A 1 cells stably transfected with 
NA TblNA T1 *X or NATalNA T1 *X was determined by western blot Cell Iysates were 
isolated as described above. Varying amounts of lysate were mixed 1: 1 with 5% 13-
mercaptoethanol in Laemmli buffer (Bio-Rad), boiled for 5 min, and resolved by 12% 
SDS-PAGE. The proteins were then transferred by semi-dry electroblotting to 
polyvinylidene fluoride (PVDF) membranes. The membranes were probed with G5, a 
monoclonal mouse anti-NAT1 (1 :200) Santa Cruz Biotechnology, Santa Cruz, CA) and 
with horseradish peroxidase (HRP)-conjugated secondary donkey anti-mouse IgG 
antibody (1 :2,000) (Santa Cruz). Supersignal West Pico Chemiluminescent Substrate 
was used for detection (Pierce). Densitometric analysis was performed using Quantity 
One Software (Bio-Rad). 
Measurement of NAT1 mRNA 
Total RNA was isolated from cells using the RNeasy kit (Qiagen) followed by 
removal of contaminating DNA by treatment with TurboDNase Free (Ambion, Austin, 
TX). Synthesis of cDNA was performed using qScript cDNA Synthesis Kit (Quanta 
Biosciences, Gaithersburg, MD) using 1 IJg of total RNA in a 20 IJL reaction per the 
manufacturer's protocol. Quantitative RT-PCR (qRT-PCR) assays were used to assess 
the relative amount of NA T1 mRNA in cells stably transfected cells. The Step One Plus 
(Applied Biosystems, Foster City, CA) was used to perform qRT-PCR in reactions 
containing 1x final concentration of qScript One-Step Fast mix (Quanta Biosciences), 
300 nM of each primer and 100 nM of probe in a total volume of 20 IJL. For qRT-PCR of 
NAT1 mRNA, a TaqMan probe was used with NAT1 Total Splice Forward and NAT1 
Total Splice Reverse primers (Table 2) designed using Primer Express 1.5 software 
(Applied Biosystems). An initial incubation at 50°C was carried out for 2 minutes and at 
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94°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
minute. TaqMan® Ribosomal RNA Control Reagents for quantitation of the endogenous 
control, 18S rRNA, (Applied Biosystems) were used to determine b.Ct (NAn ct -18S 
rRNA Ct). b.b.Ct was determined by subtraction of the smallest b.Ct and relative 
amounts of NAT1 mRNA were calculated using zMCt as previously described (Barker et 
aI., 2006). 
RNase Protection Assay 
Biotinylated RNA probes were constructed to span the region 3' to the NAT1 
ORF using the MAXlscript In Vitro Transcription kit (Applied Biosystems/Ambion, Austin, 
TX). RNase Protection Assays (RNAPs) were carried out using RPAIII Kits (Applied 
Biosystems/Ambion) according to the manufacturer's protocols. Briefly, total RNA was 
collected from transiently transfected cells CHO cells and treated with Turbo DNase 
Free kit (Applied Biosystems/Ambion). Five ~g of total RNA was allowed to hybridize 
overnight in molar excess of biotinylated RNA probes. The resulting RNA-probe mixture 
was treated with RNase AlTI (kit) to degrade any non-hybridized RNA and any 
remaining probe. The RNased hybridized mixture was then separated on a 
polyacrylamide gel and transferred to a nitrocellulose membrane. The membrane was 
detected with Chemiluminescent Nucleic Acid Detection Module (ThermoScientific) and 
exposed to x-ray film to visualize. 
Measurement of Cytotoxicity and Mutagenesis 
Assays for cell cytoxicity and mutagenesis were carried as previously described (Wu 
et aI., 1997) with slight modifications. Cells were grown in HAT medium (30 mM 
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hypoxanthine, 0.1 mM aminopterin, and 30 mM thymidine) for 12 doublings. Cells 
(1 x1 06) were plated, allowed to grow for 24 h and were then treated with 1.56, 3.13, 6.25 
or 12.5 IJM ASP (Sigma) or vehicle alone (0.5% DMSO) in media. After 48 h, cells were· 
plated to determine survival and mutagenic response to ASP. To determine cloning 
efficiency following each dose of ASP, 100 cells were plated in triplicate in 6 well-plates 
and allowed to grow for 7 days in non-selective media. Colonies were counted and 
expressed as percent of vehicle control. To determine mutagenic response following 
ASP exposure, 5x1 05 cells were plated and sub-cultured for 7 days and then seeded 
with 1x105 cells/100 x 20 mm dish (10 replicates) in complete DMEM containing 40 IJM 
6-thioguanine (Sigma). Mutant hprt cells were allowed to grow for 7 days and colonies 
were counted to determine ASP-induced mutants and corrected by cloning efficiency. 
Removal of the SV40 polyadenylation signal from NATa and NATb NAT1*10B 
Constructs 
The SV40 polyadenylation signal was removed from the NATa and NATb 
NA T1 *1 OB pcDNA5/FRT constructs by incubation at 37° with restriction enzymes, Sacll 
and Sap!. The overhangs were filled in using T 4 DNA polymerase (New England 
Siolabs) and then ligated back together using T4 DNA ligase (New England Siolabs). 
Transient transfections and PASA in vitro N-acetylation assays were performed as 
described above. 
Statistical Analysis 
Statistical differences were determined using either an unpaired Student's t-test 
or one-way ANOVA using Prism Software by Graphpad (La Jolla, CA). 
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RESULTS 
Upon sequencing two sources of NA T1 *10 genomic DNA used to create the 
NA T1 *10 constructs, 4 additional polymorph isms were found in the 3' -UTR of one of the 
sources (Table 1). In addition to T1088A (rs1057126), C1095A (rs15561), and G1191T 
(rs4986993), A1642C (rs8190865) a deletion boCT1647, and C1716T (rs8190870) and 
A 1735T. These were validated by their inclusion in the NCBI dbSNP database. 
NATblNA T1 enzymatic activity was examined with PABA, ABP, or N-OH-ABP. 
Significantly more N-acetylation activity towards PABA (Figure 4-2) and ABP (Figure 4-
3) was detected in NATbINAT1*10 and NATbINAT1*10B than in NATbINAT1*4 (p<O.05) 
in transiently and stably transfected cells. Significantly more O-acetylation of N-OH-ABP 
was detected in NATbINAT1*10 and NATbINAT1*10B than in NATbINAT1*4 (p<O.05) in 
stably transfected UV5/1A1 cells (Figure 4-3). NATaINAT1 activity was also examined 
using PABA, ABP and N-OH-ABP. Significantly more NATaINAT1*10B N-acetylation of 
PABA (Figure 4-4), ABP (Figure 4-5), and O-acetylation of N-OH-ABP (Figure 5) was 
observed when compared to NATaINAT1*4 (p<O.05) both in vitro and in situ. No 
difference was observed between NATaINAT1*10 and NATaINAT1*4 stably transfected 
cells towards the N-acetylation of PABA (Figure 4-4), ABP (Figure 4-5) or the 0-
acetylation of N-OH-ABP (Figure 4-5). 
The pcDNA5/FRT (Invitrogen) utilized in these experiments contained an SV40 
polyadenylation signal for the hygromycin cassette. To ensure there was no artifactual 
use of the SV40 polyadenylation signal, it was removed to ensure that the presence of 
NATa and NATb NAT1*10B transcripts beyond the 3rd probe was not vector induced. 
Following removal of the SV40 polyadenylation site from the pcDNA5/FRT, no difference 
was observed in PABA N-acetylation between NA T1*10B and NAT1*10B LlSV40 
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polyadenylation site in NATb (Figure 4-6a) or NATa (Figure 4-6b) transiently transfected 
UVS/1A1 cells. 
Western blots were performed to examine NAT1 protein expression in stably 
transfected UVS/1 A 1 cells (Figure 4-7). Equal amounts of total protein were loaded and 
densitometric analysis was performed using Quantity One 1-D Analysis Software (Sio 
Rad). Significantly more protein (p<O.OS) was detected in NATbINAT1*10 and 
NATblNA T1*10B than in NATbINAT1*4 transfected cells (Figure 4-7b). Significantly 
more protein was observed in NATaINAT1*10B when compared to NATalNA T1*4 
(p<O.OS) stably transfected cells (Figure 4-7c). No difference in protein (p>O.OS) was 
observed between NATalNA T1*10 and NATaINAT1*4 stably transfected cells (Figure 4-
7c). 
mRNA levels in stably transfected CHO cells were determined by RT-PCR 
(Figure 4-8). Significantly more mRNA was observed in NATbINAT1*10 and 
NA TblNA T1 *1 OB than NATblNA T1 *4 transfected cells (Figure 4-8b). Significantly more 
mRNAwas observed in NATaINAT1*10B but not NATaINAT1*10when compared to 
NATalNA T1*4 stably transfected cells. 
Stable transfection of NATbINAT1*4 and NATbINAT1*10 increased ASP-induced 
cytotoxicity (Figure 4-9a) and hprt mutants (Figure 4-9b) compared to non-transfected 
cells. Significant differences between NATblNA T1 *4 and NA Tb/NA T1 *10 were not 
observed, although, NATbINAT1*10 ASP-induced hprt mutants were higher than 
NATbINAT1*4 (Figure 4-9b). 
Three biotinylated RNA probes were used to determine the polyadenylation 
pattern of NA T1 *4, NAT1*10, and NAT1*10B (NATa and NATb constructs) in transiently 
transfected UVS/1 A 1 cells in an RNase Protection assay (Figure 4-10). RNase 
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Protection assays detected no difference in polyadenylation site usage between RNA 
isolated from CHO cells transfected with NATbINAT1*4 or NATblNA T1*10 (Figure 4-10 
b-d). Bands were detected that correspond to mRNAs utilizing polyadenylation signals 
located at positions 1028, 1088, 1209, 1248, and 1613 nts. As expected, bands 
corresponding to PolyA Signal 1 located at position 1028 (215 nucleotides), PolyA Signal 
2 located at position 1088 (284 nucleotides), PolyA Signal 3 located at position 1209 
(118 nucleotides), PolyA Signal 4 located at position 1248 (163 nucleotides) and PolyA 
Signal 5 located at position 1613 (252 nucleotides) were observed for all constructs. Full 
length probe 1 (371 nucleotides) and full length probe 2 (388 nucleotides) was observed 
for NAT1*4, NAT1*10, and NAT1*10B (NATa and NATb) (Figure 4-10 b, c). Full length 
protection of probe 3 was observed only in NA T1 *1 OB (NATa and NA Tb constructs) 
transfected cells (369 nucleotides) (Figure 4-10d). No band was observed in the lane 




NATa (Type IA) 





























Figure 4-1 Genomic organization of NAT1 gene 
(a) Genomic organization of NAT1 gene (b) Type I and Type II NAT1 transcripts (c) 
NATb and NATa NAT1 *4, NAT1 *10, and NAT1 *10B constructs . (Adapted from Butcher 
et aI. , 2005) . NAT1*10 SNPs include T1088A, C1095A, and T1191G. Additional 




































































Figure 4-2: N-acetylation of PABA by NAT1 4 and NAT110 in NATb constructs 
NATb activity. N-acetylation of PABA in UV5/1A1 cells expressing NAT1 *4 (open bars) , 
NAT1 *10 (closed bars) and NA T1*10B (grey bars). (a) PABA N-acetylation (in vitro) 
activity following transient transfection with pcDNA5/FRT; (b) PABA N-acetylation activity 
(in vitro) following stable transfection with pcDNA5/FRT; (c) PABA N-acetylation (in situ) 
following stable transfection with pcDNA5/FRT. Each bar represents mean ± S.E.M. for 
three transient transfections (a) or three separate collections performed in triplicate (b 
and c) Significantly higher than NAT1 4 denoted by *p<O.05 and ***p<O.0001 following 
















































10 50 100 








o NAT1 4 
_ NAT11 0 
Q NAT1 10B 
Figure 4-3: N- and 0- ABP acetylation by NA T1 4 and NA T1 10 in NATb constructs 
NATb activity. N- and O-acetylation of ABP and N-OH-ABP following stable transfection 
in UVS/1A1 cells transfected with NAT1 *4 (open bars), NAT1*10 (closed bars) and 
NAT1*10B (grey bars) in NATb constructs . (a) ABP N-acetylation activity (in vitro) ; (b) 
ABP N-acetylation (in situ) ; (c) O-acetylation of N-OH-ABP (in vitro) . Each bar 
represents mean ± S.E.M. for three separate collections performed in triplicate . 
Significantly higher than NAT1 4 denoted by *p<O.OS and ***p<O.0001 following analysis 




































Figure 4-4: N-acetylation by NAT1 4 and NAT1 10 in NATa constructs 
NATa activity. N-acetylation of PABA UV5/1A1 cells stably transfected with NAT1*4 
(open bars) , NAT1*10 (closed bars) and NAT1*10B (grey bars) in NATa. (a) PABA N-
acetylation activity (in vitro) and (b) PABA N-acetylation (in situ) . Each bar represents 
mean ± S.E.M. for three separate collections performed in triplicate. Significantly higher 
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Figure 4-5: N- and 0- ABP acetylation by NAT1 4 and NAT1 10 in NATa constructs 
NATa activity. N- and O-acetylation of ASP and N-OH-ASP following stable transfection 
in UVS/1A1 cells transfected with NAT1*4 (open bars) , NAT1*10 (closed bars) and 
NAT1*10B (grey bars) in NATa constructs. (a) ASP N-acetylation activity (in vitro) ; (b) 
ASP N-acetylation (in situ) ; (c) O-acetylation of N-OH-ASP (in vitro) . Each bar 
represents mean ± S.E.M. for three separate collections performed in triplicate. 
Significantly higher than NAT1 4 denoted by *p<O.05 and ***p<O.0001 following analysis 































Figure 4-6: NAT1 1 o BflSV40 N-acetylation in transiently transfected cells 
PABA N-acetylation in vitro of UVS/1A1 cells transiently transfected with NAT1*10B 
(open bars) or NAT1*10B f1SV40 polyadenylation site (closed bars) in NATb constructs 
(a) or NATa constructs (b)" Error bars represent one collection performed in triplicate 
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Figure 4-7: NAT1 protein expression of NAT1 4 and NAT1 10 
lOB 
Representative western blot of NAT1 4, NA T1 10, and NAT1 10B expression in NATb 
constructs (a) and densitometric analysis of NATb constructs (b) and NATa constructs 
(c). Each bar represents mean ± SEM of 1 or 2 western blots performed in triplicate. 
Analysis done with Quantity One software (BioRad) . Significantly higher than NAT1 4 
denoted by *p<0.05 and ***p<0.0001 following analysis with one-way ANOVA. 
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Figure 4-8: NAT1 mRNA levels of NAT1*4 and NAT1*10 
NAT1 mRNA expression levels of UVS/1A1 cells stably transfected with NAT1*4 (open 
bars) , NAT1 *10 (closed bars) or NAT1*10B (grey bars) in NATb (a) or in NATa (b) 
constructs. Each bar represents mean ± S.E.M. for 3 determinations. Significantly higher 
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Figure 4-9: ABP-induced cytotoxicity and mutants 
(a) ABP-induced cytotoxicity and (b) ABP-induced hprt mutants per million cells in 
UV5/1A1 cells stably expressing CYP1A1 only (e), CYP1A11NA T1*4 (.), and CYP1A1 
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Figure 4-10: RNase protection assay of NAT1*4, NAT1*10, and NAT1*10B 
An RNase protection assay examining pattern of polyadenylation usage. (a) Schematic 
representation of NAT1 3'-UTR and the probes used for the RNase protection assay. 
Lane 1 contains a biotinylated marker, lane 2 contains RNA isolated from transiently 
transfected with lane 2 NAT1 *4, lane 3 NAT1*10, lane 4 NAT1 *10B in NATb constructs, 
lane 5 with NA T1 *4, lane 6 with NAT1 *10, and lane 7 with NAT1 *10B in NATa 
constructs. Lanes 8-10 are control lanes; lane 8 contains yeast (no target) RNA, lane 9 
contains no RNase and lane 10 is probe alone. Lanes 2 - 8 were all hybridized to probe 
and treated with RNAse. (b) The 1st and 2nd polyadenylation sites were mapped with 
probe 1. (c) The 3rd and 4 th polyadenylation sites were mapped with probe 2. (d) The 5th 
and 6th polyadenylation sites were mapped with probe 3. 
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Table 4-1: NA T1*10 and NAT1*10B Polymorphisms 
Nucleotide Position 
Allele 1088 1095 1191 1642 1647 1716 1735 
NAT1*4 T C G A CT C A 
NAT1*10 A A T A CT C A 
NAT1*10B A A T C ~CT T T 
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Primer Use Sequence 
Lkm40P1 NATb 5-'UTR forward specific PCR 5'-GGCCGCGGCA TTCAGTCTAGTTCCTGGTTGCC-3' 
P1 Fwd Inr Nhel NATb 5'-UTR forward specific nested PCR 5'TTT AAAGCTAGCA TTCAGTCTAGTCTAGTTCCTGGTTGCCGGCT-3' 
Lkm41P3 NATa 5'-UTR forward SQ8cifc PCR 5' -GGCCGCGGAACACA TTCTGCTCAAA T AAGCCT -3' 
P3 Fwd Inr Nhel NATa 5'-UTR forward specific nested PCR 5'TT AA TGCTAGCAACACATTCTGCTCAAA T AAAGCCTAGG-3' 
NAT1 (3') ORF Rev NATa/NATb 5'-UTR reverse PCR 5'-TTCCTCACTCAGAGTCTTGAACTCTA TT -3' 
NAT1 (3') ORF For NAT1 codingregion forward PCR 5'-AGACATCTCCATCATCTGTGTTT ACTAGT-3' 
-"cDNA5 FRTdlstal Rev NAT1 3' -UTR reverse PCR 5'-CGTGGGGATACCCCCTAGA 
NAT1 KPN-Rev NAT1 3'-UTR reverse nested PCR 5'-ATAGTAGGTACCTCTGAATTATAGATAAGCAAAGATTCAGATTCT-3' 
NAT1 KPN-Rev'10B NAT1 3'-UTR reverse nested PCR 5'-ATAGTAGGTACCTCTGAATTATAGATAAGCAAAGATACAGATTCT-3' 
NAT1 total ~-'iced Forward NAT1 SQ8cific forward o-RT-PCR 5' -GAATTCAAGCCAGGAAGAAGCA-3' 
NAT1 total spliced Reverse NAT1 specific reverse q-RT -PCR 5'-TCCAAGTCCAA TTTGTTCCTAGACT -3' 
NAT1 TAO MAN probe TAO MAN probe for NAT1 total splice 6FAM-5' -CAA TCTGTCTTCTGGA TT AA-3'MGBNFO 
Table 4-2: Primers used to construct NAT1*4, NAT1*10, and NAT1*10B 
Primers used to construct NAT1*4, NAT1*10, and NAT1*10B in NATa and NATb Type 
transcript constructs and for RT -peR. These allelic constructs were then ligated into 
pcDNAS/FRT expression vectors, 
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DISCUSSION 
NA T1 *10 has been associated with higher risk for many different forms of cancer 
including breast, colorectal, prostate and urinary bladder cancers, gastric 
adenocarcinoma, and non-Hodgkins lymphoma. Several studies suggest that NAT1*10 
has higher acetylation capacity than the referent allele, NA T1 *4, (Bell et aI., 1995a), 
while others have reported no difference (de Leon et aI., 2000). Increased 0-
acetylation activity could result in an increased amount of unstable intermediates able to 
form DNA adducts. Because NA T1 *10 has a high allelic frequency in so many 
populations (Cascorbi et aI., 2001; Lo-Guidice et aI., 2000; Vaziri et aI., 2001; Zhangwei 
et aI., 2006), it is important to identify the risk that is associated with NAT1*10. To better 
understand the risk associated with NA T1 *1 0 and cancer, NA T1 *10 acetylation activity 
was studied (in vitro and in situ) using complete NATb and NATa mRNA constructs to 
better mimic in vivo acetylation. 
Differences between the referent protein, NAT1 4, and the variants, NAT1 10 and 
NAT1 10B, have been studied in UV5/1A1 CHO cells transiently and stably transfected 
with NATb and NATa type mRNA. The effect that NAT1*10 polymorph isms exert on 
mRNA and protein expression and enzymatic activity appears to be transcript 
dependent. We have shown increased N- and 0- acetylation and increased mRNA and 
protein expression for NAT1 10 and NAT1 10B when compared to NAT1 4 in cells 
transfected in the NATb type mRNA. This was observed in both transiently and stably 
transfected cells. In contrast, no significant difference was observed between NAT1 10 
and NAT1 4 in cells transfected with the NATa type mRNA. However, a significant 
difference was observed between NAT1 4 and NAT1 10B in cells transfected with the 
NATa mRNA. This effect of mRNA type on NA T1*10 polymorphisms is a novel finding. 
It is possible that mRNA type may be partly responsible for discrepancies concerning 
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NA T1 *10 phenotype. Studies have reported allele-specific differences in transcription 
factor binding levels (McDaniell et aI., 2010). It is possible that allele specific 
transcription differences could be dependent on transcript type as well. 
In addition to importance of transcript type on NA T1 *1 0 phenotype, we also 
report on additional polymorphisms located in the 3'-UTR in an allele referred to in this 
dissertation as NA T1 *1 OB. NA T1 *1 OB has 4 polymorphisms in addition to the T>A 1088, 
C>A 1095 and G> T1191 that characterize NA T1 *10. NA T1 *1 OB also includes 
A>C1642, flCT1647, C>1716, and A>T1735. Cells transfected with NAT1*10B resulted 
in increased enzymatic activity, mRNA and protein expression compared to NA T1*10. 
Because the additional polymorph isms found in NA T1 *1 OB are not routinely screened 
for, it is possible that some of the discrepancies concerning NA T1 *10 phenotype could 
also be attributed to misidentification of NA T1 *1 OB as NA T1 *10. 
There are 6 potential polyadenylation signals located in the region 3' to the NAT1 
ORF. NAT1 transcripts have been identified that utilize the first 5 of the 6 potential 
polyadenylation signals using dbSNP. The T1088A SNP present in NAT1*10 alters the 2nd 
polyadenylation signal (AAIAAA - AA8.AAA). It has been suggested (Boukouvala and 
Sim, 2005) that this change in polyadenylation signal may increase the stability of the 
NA T1 *1 0 RNA which could be responsible for any differences seen between NA T1 *1 0 
and NA T1*4 in acetylation capacity. To examine the NAT1*10 polyadenylation pattern, 
RNase Protection Assays (RNAP) were conducted. RNAP assays were carried out in 
cells transfected with NA T1 *4, NAT1*10, and NAT1*10B in both NATb and NATa 
constructs. Bands were observed corresponding to the first 5 potential polyadenylation 
signals and no qualitative differences were observed between NA T1 *4 and NA T1 *10 in 
either the NATb or NATa construct. However, there was a difference in NAT1*10B in 
both NATb and NATa constructs using probe 3. Full length protection of probe 3 was 
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observed for NA T1 *1 OB but not for NA T1 *10 or NA T1 *4 in cells transfected with both 
NATb and NATa constructs. This indicates the presence of NA T1 *1 OB transcripts that 
extend beyond probe 3. Other bands present may be due to either RNA cruciform 
structures or probe-probe interactions. While there were no quantitative differences 
observed, there could be some quantitative differences that were not large enough to be 
detected by RNAP. 
To ensure that differences in NAT1*10B activity compared to NAT1*4 and 
NA T1 *10 were not caused by the presence of the strong SV40 polyadenylation signal in 
the pcDNA5/FRT expression vector, it was removed from the vector and then ligated 
together. Transient transfections confirmed that there were no differences in NA T1 *1 OB 
with or without the presence of the SV40 polyadenylation signal. 
Because the NA T1 *10 allele has high allelic frequency in many populations, 
clearly defining the NA T1 *10 phenotype would allow cancer risk and other toxicities 
related to environmental arylamine exposure to be better understood. We have shown 
that NATblNA T1 *10 has higher enzymatic activity and mRNA and protein expression 
compared to NATblNA T1 *4. NA T1 *10 has been associated with increased risk for many 
cancers. This higher activity could be partly responsible for the increased risk 
associated for individuals possessing NA T1*10. Butcher et al. suggests that there may 
be cell-type specific expression of an RNA-binding protein that would allow increased 
mRNA stability in some cell types (Butcher et aI., 2008). It has also been suggested that 
NA T1 *10 transcripts have enhanced stability compared to NA T1 *4 in some cell lines and 
not in others. This could be reflective of cell-type specific expression of RNA-binding 
proteins that affect stability of the NAT1 transcript. Cell-type may also be important for 
differences between 5'-UTR and allele interactions. Therefore, cell-type may play an 
important role in NAT1*10 expression and activity. Future studies should be done to 
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determine in what cell types NA T1 *10 has higher levels of steady-state mRNA, protein 
and activity. Interaction of RNA-binding protein is also likely to be different between 
NATa and NATb transcripts so cell-types expressing both transcript types likely have 
complicated NA T1 *10 regulation. 
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CHAPTER 5: GENERAL DISCUSSION 
Previous studies have failed to elucidate a clear correlation between genotype 
and phenotype of NAT1 alleles. The experiments in this dissertation have examined the 
phenotype of NA T1 variant alleles, NA T1 *10, NA T1 *1 OB and NA T1 *14B compared to 
the referent, NA T1 *4. This was accomplished utilizing constructs that mimic full length 
NAT1 mRNA including the 5'-UTR, ORF, and 3'-UTR. In contrast to utilizing constructs 
that contain only the ORF, the experiments in this dissertation have allowed natural 
mRNA folding and stability to occur by utilizing full length mRNA constructs. 
Differences in NATa and NATb transcripts containing the referent allele, NA T1 *4, 
were observed. Transient and stable transfections of NATb/NA T1 *4 resulted in 
significantly more N- and 0- acetylation, protein and mRNA expression, ASP-induced 
DNA adducts and ASP-induced hprt mutants. Following studies comparing the two 
mRNA of NAT1*4, variant alleles were studied in the same NATa and NATb constructs. 
Differences in NA T1 *10 compared to NA T1 *4 were mRNA-type dependent. In 
the NATb mRNA, NA T1 *10 and NA T1 *1 OB both had higher N- and 0- acetylation, 
protein and mRNA expression than NAT1*4. In the NATa mRNA, NA T1*10B had higher 
N- and 0- acetylation, protein and mRNA expression than NA T1 *10 and NA T1 *4. There 
was no difference between NA T1 *10 and NA T1 *4 in the NATa mRNA. This finding 
emphasizes the importance of studying each allele in combination with full length mRNA. 
Failure to study mRNA type in combination with alleles may have contributed to some of 
the ambiguous results of NA T1 *10 phenotype in previous literature. Also, the additional 
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polymorphisms included in the NA T1 *108 genotype may further complicate NA T1 *1 0 
phenotype . To com prehensively study the correlation between NA T1 *10 genotype and 
phenotype, the 'studies in this dissertation reveal the need to genotype additional 
polymorph isms in the NA T1 *10 3'-UTR. 
Differences between NA T1 *4 and NA T1 *148 were observed in NATb mRNA. 
Lower Vmax for NAT1 14B toward all substrates was observed when compared with 
NAT1 4. This indicates that at high substrate concentrations, NAT1 14B has lowered 
acetylation capacity compared to NAT1 4. Lower VmaxfKm (catalytic efficiency) for NAT1 
14B toward PABA was observed when compared to NAT1 4. In contrast, higher VmaxfKm 
for NAT1 14B toward ABP and N-OH-ABP was observed when compared to NAT1 4. 
This indicates that at low substrate concentrations (concentrations well below Km) NAT1 
14B has higher acetylation capacity compared to NAT1 4. These studies revealed that 
NA T1 *148 acetylator phenotype is dependent on both substrate and substrate 
concentration. Because NAT1 14B resulted in increased ABP-induced DNA adducts, 
our results suggest that individuals possessing the NA T1 *148 allele likely have 
increased risk compared to those who are homozygous for NA T1 *4 following low 
(environmental) dose exposure to ABP. NAT1 14B is not simply associated with "slow 
acetylation" but rather is substrate dependent, since NA T1 14B exhibits lower N-
acetylation catalytic efficiency of PABA but higher N- and O-acetylation catalytic 
efficiency as well as DNA adducts following exposure to the human carcinogen ABP. 
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Limitations and recommended future studies 
The UV5 cell line is a good model for many reasons. It is a mammalian cell line, 
appropriate for studying DNA damage due to its nucleotide excision repair deficiency 
and does not endogenously express NAT1 or NAT2. However, because the 5'-UTR 
regulation reported here could be cell type specific, this regulation should be studied in 
human cell lines. Also, real-time RT-PCR on human cell lines and human tissues should 
be utilized to determine relative amounts of NATa and NATb type transcripts. This 
should be done in healthy and cancerous tissue to determine if NATa transcripts are 
upregulated differentially from NATb transcripts. This would be a start to determining the 
role of two types of transcripts. 
Efficient N-acetyltransferase purification methods would permit a more complete 
evaluation of human enzyme kinetics. All kinetic studies described in this dissertation 
were carried out with whole cell lysate. The ability to purify the NAT1 protein would 
result in more accurate characterizations. NA T1 *14B studies were only conducted in 
NATb mRNA. Future studies should be performed using NAT1*14B expressed in NATa 
mRNA. 
The only known NAT1 substrate is para-aminobenzoylglutamate (PABG), which 
is a catabolite of folate. It has been suggested that NAT1 polymorphisms are associated 
with birth defects due to the metabolism of PABG. Kinetic parameters of PABG were 
not able to be determined using current methods of HPLC separation. More sensitive 
methods of measurement are required to determine NAT1 PABG acetylation by NAT1 
expressed in UV5/1A1 cells. A colorimetric assay such as the serotonin N-
acetyltransferase (De Angelis et aI., 1998) could be adapted or developed for this 
purpose. NAT1 4 and NAT1 14B kinetic parameters for PABG should be determined as 
well as NAT1 10 and NAT1 10B PABG acetylation. 
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The in vitro kinetics were determined at 100 IJM acetyl CoA. The cellular 
concentration of acetyl CoA should be determined to better mimic in vivo kinetic 
behavior. This could be examined using an indirect detection method such as 
conversion of acetyl CoA to CoA and then reacting the CoA to NADH which can then 
react with a fluorescent probe (Abnova, Tapei, Taiwan). 
The RNase protection assays were performed with RNA from transiently 
transfected cells. More assays should be performed using stably transfected cells and 
RNA from other sources, including human tissue. Although miRNA binding sites were 
not predicted to be located on any NA T1*10 SNPs using predictive software, miRNA 
regulation of NAT1*10 should still be examined. Regulation by miRNA could be analyzed 
by northern hybridization (Lim et aI., 2003), microarray analysis (Krichevsky et aI., 2003; 
Liu et aI., 2004) or stem-loop RT-PCR (Chen et aI., 2005). 
Transcription factors associated with each transcript should also be examined. 
Because transcription factors have been shown to be allele specific (McDaniell et aI., 
2010), differences in transcription factors should be examined for each allele and in each 
transcript form. This study used NATb (type IIA) and NATa (type IA) only. Future studies 
should examine other NAT1 mRNA types in combination with variant alleles. Future 
studies should also genotype for NA T1 *1 OB separately from NA T1 *10. Because the 
NA T1*10B SNPs occur with linkage disequilibrium, this could be accomplished by 
designing an RT-PCR assay to detect C1642A as a flag SNP. 
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